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1 Introduction 
1.1 Haematopoiesis 
Blood contains several different cell types that can be classified into two main 
classes, lymphoid cells (T, B, and natural killer cells) and myeloid cells 
(granulocytes, monocytes, erythrocytes, and megakaryocytes). Each of these has a 
unique set of specialized properties and, in most cases, important life-supporting 
functions. All blood cells have a limited lifespan: several hours for granulocytes, 
several weeks for erythrocytes, and up to several years for memory T-cells.  Each 
day the body produces billions of new cells to replace blood cells lost to normal 
turnover processes as well as to illness or trauma. A variety of homeostatic 
mechanisms allow blood cell production to respond quickly to stresses such as 
bleeding or infection and then return to normal levels when the stress is resolved.  
The highly orchestrated process of blood cell production and homeostasis is termed 
haematopoiesis (fig 1.1). 
1.1.1 Haematopoietic Stem Cells 
All blood cells are produced from a small common pool of pluripotent cells called 
haematopoietic stem cells (HSC) and oligo-potent progenitors by differentiation 
(Morrison et al., 1995). The production of mature blood cells from such a pluripotent 
HSC involves a highly regulated progression through successive stages as 
commitment to a specific lineage, terminal differentiation of lineage restricted 
progenitor, growth arrest and apoptosis. The expression of different molecules on 
the surface of haematopoietic progenitors permits the interaction with various 
regulatory elements present in their environment, which includes stromal cells, 
extracellular matrix molecules and soluble regulatory cytokines as growth and 
differentiation factors. HSC are endowed with two characteristics: they give rise to 
additional HSC through self-renewal and also undergo differentiation to progenitor 
cells that become variously committed to different haematopoietic lineages 
(Weissman, 2000). These processes are under the tight control of distinct genetic 
programs with specific nuclear factors playing a key role. Operationally, HSC are 
best described as those cells capable of reconstituting the haematopoietic system of 
a recipient individual. 
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Figure 1.1 Ontogeny of haematopoietic cells from HSC. HSC can be subdivided into long-term 
repopulating HSC (LT-HSC), short-term repopulating HSC (ST-HSC) and multipotent progenitors 
(MPP). They give rise to common lymphoid progenitors (CLPs; the precursors of all lymphoid cells) 
and common myeloid progenitors (CMPs; the precursors of all myeloid cells). These progenitors 
differentiate into progressively more restricted, committed progenitors and become the mature 
haematopoietic cells of the various lineages (indicated on the right hand side). 
1.1.2 Origin of HSC 
In vertebrates, haematopoiesis occurs in successive waves during development. 
Broadly, it occurs in two phases: a transient embryonic (‘primitive’) phase of 
haematopoiesis and a subsequent definitive (‘adult’) phase. The embryonic phase of 
haematopoiesis is probably utilized to provide the embryo with its initial blood cells 
and capillary network to the yolk. The definitive phase of haematopoiesis is used to 
generate more cell types and to provide the stem cells that will last for the lifetime of 
the individual. The yolk sac is the primary site for haematopoiesis in mouse and 
human embryos and the first blood cells arise in the yolk sac blood islands (D 
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Metcalf and MAS Moore, 1971). Primitive haematopoiesis is also observed in the 
para-aortic splanchnopleura (P-SP) and the aorta-gonad-mesonephrous region 
(AGM). In contrast to the splanchnopleura, which generates multipotent 
haematopoietic cells including lymphoid progeny, the yolk sac generates only 
erythroid colonies and the CFU-mix, but no lymphoid progeny (Cumano et al., 2001). 
It has been demonstrated that the P-SP and the AGM gives rise to definitive 
multilineage haematopoiesis independently from the yolk sac. These haematopoietic 
stem cells later colonise the fetal liver, and around the time of birth, stem cells from 
the liver populate the bone marrow (BM), which then becomes a major site of blood 
formation throughout adult life. 
1.1.3 Genetic programs specifying HSC 
The production of mature blood cells from HSC requires three distinct genetic 
programs. These include: a) the specification of HSC, b) their self-renewal and c) 
their commitment/proliferation/differentiation (fig 1.2). The possible fates of 
haematopoietic stem cells are shown in figure 1.3. 
 
MaintenanceExpansion
b Self-Renewal
a Specification
c Commitment/Proliferation/ 
Differentiation
 
 
Figure 1.2 Genetic programs in haematopoiesis. At least three genetic programs are required for 
the development of the blood system (a) The specification of HSC (genesis), (b) the self-renewal, 
including expansion and maintenance of HSC, and (c) the commitment, proliferation and 
differentiation of HSC. 
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The transcriptional machinery governing early HSC function is very complex.  
Despite the progress that has been made in the recent years in identifying and 
obtaining enriched HSC populations, analysis of the population dynamics and cell 
cycle kinetics of HSCs remains difficult. Most of the studies leading to the knowledge 
of genes involved in HSC genetic programs have been carried by assaying 
haematopoietic cells from animals deficient for the gene of interest. More recently, 
expression profiling strategies have been used to determine genetic and molecular 
signatures of HSC (Ivanova et al., 2002).  
Genes involved in specifying HSC during early embryogenesis include: SCL and 
Rbtn2/Lmo-2 which are necessary for primitive and definitive haematopoiesis 
(Shivdasani et al., 1995; Warren et al., 1994). GATA-2 and AML1 are specifically 
required for definitive haematopoiesis (Okuda et al., 1996). Some other factors 
appear to be more lineage-specific in action such as GATA-3, Ikaros, PU.1, GATA-1, 
CBP, Atf4, c-myb, and E2A, and their absence affects specific haematopoietic 
lineages (Bain et al 1994, Scott 1994, Wang et al 1996 Mauoka 2002, Wang 1997, 
Emambokus 2003). After their specification in early ontogeny, HSC undergo two 
rounds of mobilization: first, to the fetal liver where they expand and second, to the 
bone marrow where they are maintained throughout adult life. Expansion of the HSC 
in the fetal liver is necessary to increase the pool size of the mobilized stem cell 
population. The genetic factors involved in regulating fetal liver HSC are: Meis1, 
which is highly expressed in fetal liver Sca-1 + Lin- cells that are enriched for HSC 
activity (Pineault et al., 2002) and Hoxb4, the overexpression of which causes in vivo 
and ex vivo expansion of HSC (Antonchuk et al., 2001; Buske et al., 2002). Hox 
proteins interact with another transcription factor Pbx which itself interacts with Meis1 
and forms a trimeric nuclear complex which is involved in target gene regulation (Liu 
et al., 2001; Swift et al., 1998).  HSC self-renewal maintenance in adult BM is 
regulated by a different set of genes. A number of recent studies point out to nuclear 
factors such as the Polycomb-Group (PcG) genes Bmi-1 and Rae-28, GATA-2 and 
TEL for potentially regulating this process. It has been observed that Bmi-1 levels 
decline during haematopoietic development, and that Bmi-1 deficient mice develop 
hypocellular BM and die at less than 2 months of age. This led to the speculation 
that Bmi-1 is involved in maintenance of the HSC pool (Lessard et al., 2004). Rae-
28, a known nuclear partner of Bmi-1 also plays a crucial role in maintaining the 
activity of HSC during fetal haematopoiesis (Ohta et al., 2002). The zinc-finger 
transcription factor GATA-2, a member of GATA family, plays a critical role in 
Introduction 
maintaining the pool of multipotent progenitors and HSC, both during embryogenesis 
and in the adult (Tsai et al., 1994).  
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Figure 1.3 Possible HSC fates. HSCs are characterized by increased cell cycle quiescence 
compared to other cells. They can remain in quiescence, enter cell cycle to undergo symmetric or 
asymmetric division, or undergo apoptotic death. Division results in daughter stem cells or mature 
cells through symmetric division or both through asymmetric division. 
 
The commitment and differentiation of haematopoietic lineages from common multi-
potential progenitors cells require the role played by lineage-specific transcription 
factors. The zinc-finger transcription factor GATA-1 and its transcriptional cofactor 
called Friend of GATA-1 (FOG-1), have been found to be essential for erythroid and 
megakaryocytic differentiation (Pevny et al., 1991; Tsang et al., 1998; Vyas et al., 
1999). PU.1 is a member of the Ets family of transcription factors and is essential in 
the development of cells of the monocytic, granulocytic and lymphoid lineages (Scott 
et al., 1994).  
1.1.4 Characterization of HSC 
HSC are rare during the postnatal life, with estimates varying from less than 0.05% 
to up to 0.5% of the total cells in the bone marrow. The majority of them normally 
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remains quiescent, as shown by their resistance to treatment with 5-fluorouracil, 
which eliminates dividing cells without adversely affecting the long-term repopulating 
capability of the bone marrow. Identification and isolation of HSC relies on the 
development of quantitative and specific assays for these cells. A proof of the 
existence of HSC requires the demonstration of its ability to produce a long-lasting 
multilineage clone in vivo. Various types of syngenic and xenogenic models have 
been developed to detect human and animal HSC based on this definition (Dick et 
al., 1997; Eaves et al., 1997; Zanjani, 1997). Although HSC can be defined using in 
vivo models, there is as yet no in vitro assay that specifically detects HSC. The 
existing in vitro assays are only able to detect the intermediate progenitors that 
develop from the HSC ((fig 1.4). 
 
In vivo models: Haematopoietic stem cells are defined in repopulation assays 
based on their functional ability to home to the bone marrow microenvironment and 
to repopulate transplanted recipients durably with both myeloid and lymphoid cell 
populations (Moore, 1997). In order to study human haematopoiesis using in vivo 
models, two essential prerequisites need to be met: The host should not eliminate 
the xenograft via an immune reaction and should provide a permissive 
microenvironment for engraftment and multilineage differentiation of donor cells. 
Various animal models such as fetal lambs, dogs, and immunodeficient mice have 
been tried for in vivo functional assays of human HSC (Berenson et al., 1987; 
Berenson et al., 1988; Eaves et al., 1997; Zanjani et al., 1997). Spontaneous mutant 
mouse models, having multiple defects in immunity, partially meet these criteria and 
have been modified to improve their model function.  The NOD1/ LtSz-SCID mouse, 
generated by crossing the SCID2 mutation from C.B-17- scid mice onto the NOD 
background, is widely being used to study reconstitution with human haematopoietic 
cells (Larochelle et al., 1996; Conneally et al., 1997). The cells capable of 
multilineage repopulation of transplanted NOD/SCID mice are termed as SCID 
 
 
 
1 Non obese diabetic (NOD) mice are animal models of spontaneous autoimmune T-cell mediated 
insulin dependent diabetes mellitus (IDDM). 
2 Severe combined immunodeficiency disease. (SCID). SCID mice fail to develop T and B cells. This 
defect is due to failure in VDJ recombination. Since the mice lack T and B cells of their own, they do 
not reject the transplanted human tissues and therefore could be used for such studies. 
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repopulating cells (SRC) (Peled et al., 1999) and occur at low frequencies in the 
order of 1 in 9.3 x 105 mononuclear cord blood cells and 1 in 3.0 x 106 normal bone 
marrow cells (Wang et al., 1997). There are some limitations with this assay as 
NOD/SCID mice develop thymic lymphomas at an early age and consequently 
mortality increases from the 3rd month of their life. For this reason long term studies 
are not possible unless serial transplantation is performed. In addition, the 
differentiation of human haematopoietic cells is skewed towards the B-lymphoid 
lineage raising some concerns about the normal development of human stem cells in 
the murine environment. The recently developed 2 microglobulin knockout 
NOD/LtSz-SCID B2mnull mice (NOD/SCID/B2mnull) and the NOD/SCID/γcnull  both 
lacking natural killer (NK) cell activity show better engraftment of human cells than 
NOD/SCID mice, but have shorter survival (Christianson et al., 1997). 
NOD/SCID/B2mnull and NOD/LtSz-SCID transgenic for human growth factors have 
been studied for the engraftment of human AML cells (Feuring-Buske et al., 2003). 
The NOD/SCID/B2mnull mouse has been reported to require more than 4 to 30-fold 
less human cells to reach similar levels of human engraftment (Kollet et al., 2000). 
However, the SRC giving human reconstitution in these mice has been shown to 
include cells expressing CD38, while SRCs in the NOD/SCID model are exclusively 
CD38 negative. These observations suggest that less primitive progenitors represent 
the predominant human repopulating cells in NOD/SCID/B2mnull mice (Glimm et al., 
2000). 
The fetal sheep model provides an alternative to the murine xenotransplantation 
models. Zanjani et al, showed that human HSC can be transplanted intraperitoneally 
into unconditioned, early gestational sheep foetuses (Zanjani et al., 1995; Zanjani, 
2000). In this model low numbers of selected progenitors can engraft, and myelo-
erythroid as well as T and B lymphoid read-out can be monitored over several years.  
 
In vitro assays: The first in vitro assays for haematopoietic progenitors were 
developed way back in the 1960’s. Most of these assays were originally developed 
for the murine stem cells but subsequently adapted for the detection of similar 
human cell populations. All of the assays measure some aspect of stem cell activity 
and identify cells with one or more stem cell attributes. Some of these assays may 
detect similar or at least overlapping populations.  
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Long term culture initiating cell (LTC-IC) assay: Perhaps the most frequently used 
method for assessing the frequency of primitive cells in vitro is the long-term culture 
initiating cell (LTC-IC) assay. This assay is based on the observation that the bone 
marrow stromal cells can support the survival of primitive haematopoietic cells for 
several weeks. Candidate cells are primarily cultured for 5-8 weeks on adherent, 
bone marrow-derived stromal cells that presumably resemble a bone marrow-like 
environment (Dexter et al., 1977). In a second step cells are transferred into 
semisolid medium containing cytokines. As the clonogenic cells initially present in a 
cell suspension are not able to survive a period of more than ~3 weeks, the 
clonogenic cell output after 5 to 8 weeks can be used to quantify the number of 
primitive LTC-IC present at the time of culture initiation. LTC-IC assays can detect 
some but not all HSC. Although the murine LTC-IC can regenerate haematopoiesis 
in an irradiated mouse (Ploemacher et al., 1991), this property has not been 
demonstrated for human LTC-IC. Part of the human LTC-IC compartment is 
considered to be quite distinct from cells with marrow repopulating ability as shown 
by cell fractionation and some gene marking techniques (Dexter et al., 1977; 
Larochelle et al., 1996). The human LTC-IC population therefore probably represents 
a less primitive cell within the stem cell compartment.  
 
Colony Assay: Another extensively used assay, the colony forming cell (CFC) assay, 
allows the enumeration of more mature progenitor cells capable of forming colonies 
when cultured in semisolid media. These semisolid media reduce cell mobility and 
allow individual cells to develop into colonies of differentiated daughter cells. The 
morphology of colonies is distinct from one another and helps in identifying the type 
of colony being assessed. Since the HSC divide poorly in semisolid media and are 
themselves unable to form colonies, the CFC are considered to comprise a large, 
intermediate progenitor compartment that spans the entire stepwise process of 
lineage restriction. 
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Undifferentiated
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Figure 1.4 Various classes of haematopoietic stem/progenitor cells identified in vitro and in 
vivo assays. Cells have been placed on the vertical axis according to their maturation stage. 
Examples of commonly used combinations of cell surface antigens for identifying cells at distinct 
stages of differentiation are shown on the left. Assays for competitive repopulating unit (CRU) and 
NOD/SCID mouse repopulating cell (SRC) identify repopulating stem cells. Assays for Long-Term 
Culture-Initiating Cells (LTC-IC) and Cobblestone Area Forming-Cells (CAFC) identify similar 
populations of very primitive progenitor cells. High Proliferative Potential Colony-Forming Cells (HPP-
CFC) and Colony-Forming Unit- Granulocyte, Erythrocyte, Macrophage, Megakaryocyte (CFU-
GEMM) are multi-potential progenitors and are considered more primitive than the more lineage-
restricted CFU-GM, CFU-G, CFU-M, CFU-Megakaryocyte (CFU-Mk), Burst-Forming Unit-Erythroid 
(BFU-E) and CFU-E. Mature cells are identified by their morphology, functional properties and 
expression of lineage-specific antigens (Adapted from (Coulombel, 2004) and Stem Cell Technologies 
Catalogue). 
1.1.5 Surface marker analysis of HSC 
Despite many exhaustive studies, researchers have not been able to identify a 
reliable direct marker for HSC. However, there are several markers whose 
expression is gained or lost at different rates as HSC differentiate (Wognum et al., 
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2003). By targeting various combinations of markers, it has thus become possible to 
obtain fractions of cells with HSC characteristics. Some of the important markers 
currently used for HSC specification are: 
 
CD34: The CD34 antigen is the major positive marker for human haematopoietic and 
progenitor cells and has been widely used for the isolation of these cells. Among 
non-haematopoietic tissues, CD34 is expressed on endothelial cells of microvessels 
and is the ligand for L-selectin (CD62L) (Fina et al., 1990). Of haematopoietic cells in 
human fetal liver, cord blood, and bone marrow, 0.5-5% express CD34 (Civin et al., 
1984; Krause et al., 1996). However, the CD34+ cells are heterogeneous and include 
committed progenitors (Hao et al., 1995). By assessing the coexpression of other 
cell surface markers, it is possible to obtain cell fractions that are more highly 
enriched for primitive cells. CD34+ cells that do not express mature lineage markers 
(Lin-, as CD3, CD4, CD8, CD19, CD20, CD56, CD11b, CD14, and CD15) and CD38 
contains single cells with in vitro bilineage, lymphoid (B/NK) and myeloid differential 
potential (Bhatia et al., 1997; Hao et al., 1995; Waller et al., 1995). Expression of 
CD38 is correlated with increased differentiation; only a small fraction (1-10%) of 
CD34+ cells do not express CD38 (Hao et al., 1995). Both the CD34+ CD38- and the 
CD34+ CD38+ fractions contain CFC and the LTC-ICs.  The SRC are exclusively 
found in the cell fraction that expresses high levels of CD34 and no CD38 (Conneally 
et al., 1997).  
 
CD133: CD133 (Prominin-1 or AC133) is a 120-kDa cholesterol-binding glycoprotein 
(Roper et al., 2000; Weigmann et al., 1997) that belongs to a growing family of 
pentaspan membrane proteins expressed throughout the animal kingdom (Fargeas 
et al., 2003). CD133 is expressed on several primitive cells such as haematopoietic 
stem and progenitor cells derived from bone marrow, fetal liver, and peripheral blood 
(Yin et al., 1997), as well as neural and endothelial stem cells (Peichev et al., 2000; 
Uchida et al., 2000). CD133 is expressed on a majority of, but not all, CD34+ cells. 
These include repopulating cells, immature progenitors, and monocytes/granulocyte 
progenitors, but not most erythroid progenitors. A subpopulation of CD34- CD133+ 
lineage- cells has been described in human cord blood which might be hierarchically 
more primitive than CD34+ cells (Gallacher et al., 2000).  
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C-KIT: C-KIT or CD117 is the receptor for stem cell factor. C-KIT is expressed on 
~2-3 % of CD34+ cells including most lineage committed progenitor cells, and is 
selectively upregulated  in terminally differentiating erythroid cells but is absent from 
virtually all circulating mature blood cells (Kawashima et al., 1996). However, the 
level of expression of C-KIT on CD34+ cells is usually high enough to allow its use in 
haematopoietic cell isolation methods.  
1.1.6 Other features of haematopoietic stem cells 
Aldehyde dehydrogenase expression:  
The detoxifying enzyme aldehyde dehydrogenase (ALDH) is expressed at high 
levels in the human haematopoietic progenitors, and increased cytosolic ALDH 
activity confers resistance of HSC to alkylating agents such as cyclophosphamide 
(Kastan et al., 1990; Gordon et al., 1985). Aldefluor, a fluorescent substrate of ALDH 
has been used to isolate cells with increased ALDH activity by FACS (Storms et al., 
1999). Using a 2-step strategy consisting of lineage depletion followed by the 
selection of cells with high and low ALDH activity (ALDH hi Lin- and ALDH low Lin-), 
Hess et al isolated a functional population of haematopoietic stem and progenitor 
cells from human UCB (Hess et al., 2004) (fig 1.5). ALDH hi Lin- cells highly 
expressed primitive cell surface markers (CD34+ CD38- and CD34+ CD133+) and 
demonstrated enhanced in vitro clonogenic progenitor capacity similar to that of 
lineage depleted CD34+ CD38- cells.  Transplantation of purified ALDH hi Lin- cells 
into NOD/SCID and NOD/LtSz-SCID B2mnull mice resulted in multilineage 
haematopoietic engraftment (Hess et al., 2004). 
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Figure 1.5 Phenotypic analysis of purified ALDHhiLin- and ALDHlow Lin- populations (Adapted 
from Hess et al., 2005).  
 
Side Population phenotype and the expression of ATP Binding Cassette 
Proteins:  
Primitive haematopoietic cells from mouse, humans and other species have also 
been identified and isolated based on their ability to efflux certain fluorescent dyes, 
such as Rhodamine-123 (Rho) and Hoechst 33342.  Adult human HSC are mostly 
Rho-/low and this phenotype has been attributed to the expression of P-glycoprotein, 
an ABC transporter expressed on the cell surface.  Mice lacking P-glycoprotein are 
functionally normal but are Rho- (Uchida et al., 2002). Adult BM of many species 
have been shown to contain a rare population of Hoechst 33342-/low cells that have 
been designated as side population (SP) cells because they form a characteristic 
cluster of events off to the lower left side in dual wavelength FACS dot-plot profiles of 
Hoechst 33342 stained cells (fig 1.6). The ability of SP cells to efflux Hoechst 33342 
is due to the activity of another ABC transporter, the ABCG2. SP cells are highly 
enriched for HSC activity and represent about 0.05% of adult nucleated bone 
marrow cells in mice (Goodell et al., 1996). SP stem cells have been identified in 
haematopoietic compartments of humans, rhesus monkeys and swine (Storms et al., 
2000; Uchida et al., 2001). In human fetal liver, all of the cells that are capable of 
engrafting NOD/SCID mice were located in the 10% of CD34+ CD38- that display an 
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SP phenotype (Uchida et al., 2001). SP cells have also been demonstrated in non-
haematopoietic tissues such as skeletal muscles (Gussoni et al., 1999; Jackson et 
al., 1999) and neuronal tissues (Islam et al., 2005). This suggested that SP cells 
represent a distinct class of tissue-specific stem cells, perhaps present several 
different tissues (Zhou et al., 2001) and that this phenotype could be used as stem 
cell purification marker.  
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Figure 1.6 Hoechst SP analysis of mouse BM cells. Whole BM of mice is labelled with membrane 
permeating DNA-binding dye Hoechst 33342 and excited with 50 mW of UV (351–364 nm), and then 
the emission was detected through a 450/20-nm (Hoechst blue) band-pass filter and a 675-nm 
(Hoechst red) long-pass filter on an ultraviolet laser equipped flow cytometer. All of the parameters 
were collected using linear amplification in list mode and displayed in a Hoechst blue versus Hoechst 
red dotplot to visualize SP. A very small population of cells extrudes this dye via the ABC transporter 
ABCG2 and forms a dim tail extending from the normal G1 cell population. This population is termed 
as the side population (SP).  
 
In section 1.2 ABC proteins will be described in detail with particular emphasis on 
ABCG2, the molecular determinant of SP phenotype. 
1.1.7 Sources of HSC 
Although BM is the primary source of HSC during the postnatal life, various 
alternative sources are available for clinical and experimental use of HSC. These 
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alternative sources of HSC are mobilized peripheral blood, umbilical cord blood 
(UCB) and fetal liver.  
Bone Marrow: 
In adults, haematopoiesis is exclusively accomplished by HSC residing in the bone 
marrow. Till and McCulloch demonstrated more than 40 years ago, that a single 
precursor cell exists in the bone marrow (BM) of adult animals that is capable of both 
extensive self-renewal and multi-lineage differentiation (TILL and McCULLOCH, 
1961). With this began the understanding of both bone marrow transplantation and 
BM derived stem cells. For more than 30 years, bone marrow transplantation has 
been used to treat blood diseases such as leukemia and other disorders of the 
immune system. Although in an adult human the amount of active bone marrow is 
about 2,600 g, with approximately 1.3 x 1012 marrow cells, HSC constitute only up to 
0.5% of the cells. The majority of the HSC in BM remains normally quiescent, as 
demonstrated by their resistance to treatment by 5-fluorouracil or 4-
hydroxyperoxycyclophosphamide, which eliminates dividing cells without adversely 
affecting the long-term repopulating capability of the BM.  HSC from bone marrow 
are easy to isolate and can be transferred from the donor to the recipient with 
virtually no manipulation because the haematopoietic system has a high rate of 
renewal normally. For any type of stem cell transplantation, however, certain 
considerations must be taken into account if they are to obtain a successful graft. 
These factors include matching the HLA type of the donor with that of the recipient, 
determining the critical numbers of stem cells required and the use of accessory 
cells or factors. 
Peripheral Blood: 
Normal peripheral blood contains about 0.06% circulating HSC. However, 
temporarily shifting HSC, from extravascular BM sites into the circulating blood by 
using cytokine treatment dramatically increases the circulating stem cell 
concentration and easily compensates for the low baseline circulating CD34+ cell 
concentration. When healthy donors are treated with recombinant human 
granulocyte colony stimulating factor (rhG-CSF; 12 mg/kg per day) over 3 days, with 
another rhG-CSF dose given on the fourth day before the stem cell apheresis 
procedure, the mean peripheral blood (PB) CD34+ cell concentration increases from 
3.8 x 109/L to 61.9 x 109/L, a 16.3-fold increase over baseline. The increase in early 
CD34+38- progenitor cells is, at 23.2-fold, even greater (Korbling et al., 1995).  
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Autologous and allogenic mobilized PB HSC is commonly used for transplantation 
therapy as it has the advantage of a more rapid haematopoietic recovery compared 
to bone marrow transplantation. 
Umbilical Cord Blood: 
Umbilical cord blood (UCB) is another important source of stem cells. Approximately 
30% to 45% of all blood associated with a fetus is circulating in the umbilical cord 
and in the placenta. At the time of birth this blood is usually discarded. Being rich in 
HSC it is however, collected for experimental and clinical use. Multiple studies 
exploring the nature of UCB HSC have shown a higher proportion of primitive 
haematopoietic progenitors in UCB, with superior in vitro proliferative responses and 
in vivo engraftment capacity compared to adult BM (Leung et al., 1998; Lewis and 
Verfaillie, 2000; Mayani and Lansdorp, 1998). UCB is considered a valuable source 
for stem cell-based therapies, particularly because it is easily available, non-invasive, 
and less immunogenic compared to other sources for stem cell therapy such as bone 
marrow (Roncarolo et al., 1994). However, a single cord may not contain sufficient 
total number of HSC for fast and durable engraftment in adult patients (Rubinstein et 
al., 1998). Methods for ex vivo expansion of these HSC are being evaluated. 
1.2 ABC proteins 
The ATP-binding cassette (ABC) proteins represent the largest family of 
transmembrane proteins. These proteins bind ATP and use the energy to translocate 
various molecules across extra- and intracellular membranes (Higgins, 1992). These 
are classified as ABC transporters based on the sequence and organization of their 
ATP-binding domains, also known as nucleotide binding domains (NBD). The NBD 
are highly conserved and contain characteristic Walker A and B motifs, separated by 
about 90-120 amino acids. They also contain an additional element, the signature 
(C) motif, located close to the Walker B motif. The eukaryotic ABC proteins are 
organized either as full transporters or as half transporters (Hyde et al., 1990) (fig 
1.7). The translocator component of a full ABC transporter is composed of two multi-
transmembrane domains (TMD) and two NBD.  Half transporters consist of one TMD 
and NBD, and require the formation of a homo- or heterodimer to form a functional 
transporter. The TMD consist of 6-11 membrane spanning α-helices and provide the 
specificity for the substrate. The conformational changes within the TMD are 
Introduction 
believed to be responsible for the transport of molecules through these transporters. 
The NBDs are located on the cytoplasmic side and hydrolyse the cytoplasmic ATP to 
derive energy for the active transport of substrates across the membranes.  
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Figure 1.7 Structural organisation of ABC Transporters. (A) ABC transporters having two TMD 
and two NBD. The NBD are located at the cytoplasmic surface of the membrane and contain the 
highly conserved ABC signature and the Walker A and B motifs which are involved in ATP hydrolysis. 
The most conserved residues in these motifs are indicated. (B) ABC half transporter having one NBD 
and one TMD. (Modified from H Bolhuis et al., FEMS 1997) 
 
These transporters are mostly unidirectional and the transport can take place against 
considerable concentration gradients. In bacteria, they are predominantly involved in 
the import of essential compounds that cannot be obtained by diffusion such as 
sugars, vitamins, metal ions, etc., into the cells. In eukaryotes, most ABC 
transporters move the compounds from the cytoplasm, to the outside of the cell or 
into an intracellular compartment. Most of the known functions of eukaryotic ABC 
transporters involve the shuttling of hydrophobic compounds either within the cell as 
part of a metabolic process, or outside the cell for transport to other organs or for 
secretion from the body. 
The human ABC protein family currently comprises 48 members and can be 
subdivided into seven distinct subfamilies, based on similarity in gene structure, 
organization of domains as well as sequence homology in the NBD and the TM 
domains (Dean et al., 2001). As per the HUGO Gene Nomenclature, the 7 
subfamilies of human ABC genes are termed ABCA (12 members), ABCB (11 
members), ABCC (13 members), ABCD (4 members), ABCE (1 member), ABCF (3 
members), and ABCG (5 members). A list of all known human ABC genes including 
a concise summary of each subfamily is displayed in table 1.1. 
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Table 1.1 List of Human ABC Genes, Chromosomal location, and Function (Dean et al., 2001). 
Gene Alias Location Subfamily Expression Function 
ABCA1 ABC1 9q31.1 ABC1 Ubiquitous Cholesterol efflux onto HDL 
ABCA2 ABC2 9q34 ABC1 Brain Drug resistance 
ABCA3 ABC3, ABCC 16p13.3 ABC1 Lung  
ABCA4 ABCR 1p22.1-p21 ABC1 Photoreceptors N-retinylidene-PE efflux 
ABCA5  17q24 ABC1 Muscle, heart, testes  
ABCA6  17q24 ABC1 Liver  
ABCA7  19p13.3 ABC1 Spleen, thymus  
ABCA8  17q24 ABC1 Ovary  
ABCA9  17q24 ABC1 Heart  
ABCA10  17q24 ABC1 Muscle, heart  
ABCA12  2q34 ABC1 Stomach  
ABCA13   7p11-q11 ABC1 Low in all tissues   
ABCB1 MDR1, PGY1, PGP 7p21 MDR HSC, Adrenal, kidney  Multidrug resistance 
ABCB2 TAP1 6p21 MDR All cells Peptide transport 
ABCB3 TAP2 6p21 MDR All cells Peptide transport 
ABCB4 PGY3 7q21.1 MDR Liver PC transport 
ABCB5  7p14 MDR Ubiquitous  
ABCB6 MTABC3 2q36 MDR Mitochondria Iron transport 
ABCB7 ABC7 Xq12-q13 MDR Mitochondria Fe/S cluster transport 
ABCB8 MABC1 7q36 MDR Mitochondria  
ABCB9  12q24 MDR Heart, brain  
ABCB10 MTABC2 1q42 MDR Mitochondria  
ABCB11 SPGP 2q24 MDR Liver Bile salt transport 
ABCC1 MRP1 16p13.1 CF/MRP Lung, testes, PBMC Drug resistance 
ABCC2 MRP2 10q24 CF/MRP Liver Organic anion efflux 
ABCC3 MRP3 17q21.3 CF/MRP Lung, intestine, liver Drug resistance 
ABCC4 MRP4 13q32 CF/MRP Prostrate Nucleoside transport 
ABCC5 MRP5 3q27 CF/MRP Ubiquitous Nucleoside transport 
ABCC6 MRP6 16p13.1 CF/MRP Kidney, liver  
CFTR ABCC7 7q31.2 CF/MRP Exocrine tissue Chloride ion channel 
ABCC8 SUR 11p15.1 CF/MRP Pancreas Sulfonylurea receptor 
ABCC9 SUR2 12p12.1 CF/MRP Heart, muscle  
ABCC10 MRP7 6p21 CF/MRP Low in all tissues  
ABCC11 MRP8 16q11-q12 CF/MRP Low in all tissues  
ABCC12 MRP9 16q11-q12 CF/MRP Low in all tissues   
ABCD1 ALD Xq28 ALD Peroxisomes VLCFA transport regulation 
ABCD2 ALDL1, ALDR 12q11-q12 ALD Peroxisomes  
ABCD3 PXMP1, PMP70 1p22-p21 ALD Peroxisomes  
ABCD4 PMP69, P70R 14q24.3 ALD Peroxisomes   
ABCE1 OABP, RNS41 4q31 OABP Ovary, testes, spleen Oligoadenylate binding protein 
ABCF1 ABC50 6p21.33 GCN20 Ubiquitous  
ABCF2  7q36 GCN20 Ubiquitous  
ABCF3   3q25 GCN20 Ubiquitous   
ABCG1 ABC8, White 21q22.3 White Ubiquitous Cholesterol transport 
ABCG2 ABCP, MXR, BCRP 4q22 White Placenta, intestine, HSC Toxin efflux, sterol transport 
ABCG4 White2 11q23 White Liver  
ABCG5 White3 2p21 White Liver, intestine Sterol transport 
ABCG8   2p21 White Liver, intestine Sterol transport 
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ABC genes that are over-expressed in HSC and determine the drug and dye efflux 
properties of stem cells are MDR1 and ABCG2: 
1.2.1 Multidrug resistance 1 (ABCB1):  
Multidrug resistance1 (MDR1; ABCB1), formerly known as PGP was the first human 
ABC transporter cloned and characterized through its ability to confer a multidrug 
resistance phenotype to cancer cells that had developed resistance to chemotherapy 
drugs (Juliano and Ling, 1976). MDR1 has been demonstrated to be a promiscuous 
transporter of hydrophobic substrates, hydrophobic drugs including colchicine, VP16, 
adriamycin and vinblastine as well as lipids, steroids, xenobiotics, and 
peptides(Ambudkar, 1998). The gene is thought to have an important role in 
removing toxic metabolites from cells, but is also expressed in cells at the blood–
brain barrier and presumably has a role in transporting compounds into the brain that 
cannot be delivered by diffusion. MDR1 has been shown to affect the pharmacology 
of the drugs that are substrates (Hoffmeyer et al., 2000). Chaudhary and Roninson 
were the first to demonstrate that the MDR1 is highly expressed in CD34+ 
haematopoietic stem cells (Chaudhary and Roninson, 1991), suggesting that efflux 
pump activity could be responsible for the low retention of Rho123 in primitive 
haematopoietic cells. Experiments involving overexpression of MDR1 in HSC 
demonstrate an expansion of transduced cells in 12-day cultures as well as 
increased repopulating activity in vivo (Bunting et al., 2000). Mice receiving MDR1-
transduced cells developed a myeloproliferative disorder characterised by high 
peripheral white blood cell counts and splenomegaly due to myeloid progenitor 
accumulation at both sites (Bunting et al., 1998; Bunting et al., 2000), indicating that 
ABC proteins might play a role in haematopoietic development. 
1.2.2 ABCG2: 
ABCG2, commonly known as Breast Cancer Resistance Protein (BCRP), is a 
member of the G-subfamily of ABC proteins. A brief introduction to G-subfamily is 
essential for understanding the uniqueness of ABCG2: The human ABCG subfamily 
comprises five members (ABCG1, ABCG2, ABCG4, ABCG5 and ABCG8). Members 
of this family are unique in their domain organization; they are "reverse" half 
transporters that have a single NBD at the N terminus and a TMD at the C terminus. 
Most of the human ABCG proteins seem to be involved in lipid and/or sterol 
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transport. The ubiquitously expressed ABCG1 and the liver specific ABCG4 are 
thought to be involved in cellular cholesterol transport. ABCG5 and ABCG8 arranged 
head-to-head with each other on chromosome 2p15-p16, heterodimerise together 
and are thought to transport non-cholesterol sterols (sitosterols). ABCG2 mediates 
resistance to multiple chemotherapeutic agents by pumping them out of the cells and 
thus lowering their cytotoxic effects. More recently ABCG2 has been shown to 
transport protoporphyrins and sulphated estrogens (Jonker et al., 2002; Imai et al., 
2003). 
1.2.3 Organisation of ABCG2 gene and regulation: 
ABCG2 was first described by Allikmets et al. as an ABC transporter gene highly 
expressed in placenta and was named ABCP (Allikmets et al., 1998). The ABCG2 
gene contains 16 exons spanning 66 kb and was mapped to human chromosome 
4q22 (fig 1.8). It produces two transcripts that differ at the 5’-end, but encode the 
same protein consisting of 655 amino acids. Characterization of the ABCG2 
promoter revealed that it is a TATA-less promoter with several Sp1, AP1 and AP2 
sites and a CCAAT box downstream of a putative CpG island (Bailey-Dell et al., 
2001).  A putative estrogen response element (ERE) has been found recently. It has 
been demonstrated that ABCG2 mRNA expression was induced by 17β-estradiol 
(E2) in estrogen receptor (ER)-positive cell lines and that this effect can be reversed 
by the antiestrogens (Ee et al., 2004). 
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Figure 1.8 Diagram of genomic organisation of the ABCG2 and primary structure of ABCG2 
protein. The exons are numbered. The lower panel shows relations between coding regions and the 
protein domain organisation. Positions of single nucleotide polymorphisms (SNP) are indicated. NBD 
indicates the nucleotide binding domain; TM represents transmembrane region. Acquired mutations 
observed in some drug selected cell lines are indicated in italics. (Adapted from Doyle and Ross, 
2003). 
 
Recent evidence suggests that ABCG2 functions as a homodimer bridged by 
disulphide bonds. Under reducing conditions in the SDS-PAGE, ABCG2 protein 
migrates as a 70 kDa band but in non-reducing conditions, as a 140 kDa complex. 
The 140 kDa ABCG2 complex dissociates into 70 kDa polypeptides with the addition 
of 2-mercaptoethanol indicating the presence of ABCG2 as homodimer. The 
functional activity of ABCG2 in transfected insect cells, using a baculovirus-Sf9 cell 
system, indicates the activity of the protein as a homodimer as in this heterologous 
system, it is unlikely that any possible heterodimeric partners of ABCG2 are 
expressed (Ozvegy et al., 2001; Ozvegy et al., 2002). 
1.2.4 Tissue distribution of ABCG2: 
Cellular localization studies using monoclonal and polyclonal antibody probes 
confirm the predominant plasma membrane localization of ABCG2 transporter 
(Rocchi et al., 2000; Scheffer et al., 2000). ABCG2 expression analysis in normal 
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tissues using Northern blots reveal high expression in placental tissue, parts of brain 
and liver (Doyle et al., 1998). Using commercially available multiple tissue dot blots 
and ABCG2 cDNA as probe, Doyle et al. showed highest level of expression in 
placenta, followed by liver and small intestine. Certain parts of the brain (putamen, 
substantia nigra, pituitary gland, thalamus, amygdala, caudate and subthalamic 
nuclei) also show relatively high expression of ABCG2 mRNA. Immunohistochemical 
studies with BXP-21 and BXP-34 show moderate to strong expression in many 
normal tissues, for instance in the apical membrane of the placental 
syncytiotrophoblasts, on the bile canalicular membrane of the hepatocytes, on the 
apical side of the villous epithelial cells in the intestine and colon, in cardiac muscle, 
in pancreatic endocrine cells and in the endothelial cells of almost all tissues 
including the brain microvessels (Cooray et al., 2002; Diestra et al., 2002; 
Maliepaard et al., 2001).  
1.2.5 Multidrug resistance: 
Cells exposed to toxic compounds can develop resistance by a number of 
mechanisms including decreased uptake, increased detoxification, alteration of 
target proteins, or increased excretion. Several of these pathways can lead to 
multidrug resistance (MDR), in which the cell is resistant to several drugs in addition 
to the initial compound. This is a particular limitation to cancer chemotherapy. ABC 
genes have an important role in MDR and at least six genes are associated with 
drug transport (table 1.1). The overexpression of ABCG2 was observed in certain 
drug resistance cell lines and tumours, providing a multidrug resistance phenotype in 
these cancer cells. ABCG2 has the ability to confer high levels of resistance to 
mitoxantrone, anthracyclines, doxorubicin, daunorubicin, bisantrene, and the 
camptothecins topotecan and SN-38. ABCG2 expression also results in diminished 
intracellular accumulation of Hoechst 33342 (Kim et al., 2002). In certain drug-
selected cell lines, overexpressing human or mouse ABCG2, a single amino acid 
change in amino acid position 482 occurred (Allen et al., 2002; Honjo et al., 2001). 
The mutants having R482G or R482T showed altered substrate specificity as 
compared to the wild-type protein, i.e. they conferred increased mitoxantrone or 
doxorubicin resistance and rhodamine 123 export capacities (fig 1.9). These R482 
mutants show increased transport and ATP hydrolytic activity, therefore they are 
considered as “gain of function” mutants (Ozvegy et al., 2002).  
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Figure 1.9 ABCG2 substrates. Transported substrates of the wild-type and R482G ABCG2 protein 
(Sarkadi et al., 2004). 
 
ABCG2 is relevant in several pharmacological areas similar to the well defined 
ABCB1 (P-glycoprotein). By efflux of some cytotoxic agents from cancer cells it 
renders these cells resistant to chemotherapy. Through the same efflux mechanism, 
ABCG2 affects pharmacokinetic parameters of substrate drugs, such as intestinal 
absorption/bioavailability, hepatic/renal elimination and plasma clearance. It also 
helps protect sensitive body compartments from potentially harmful xenobiotics. 
1.2.6 ABCG2 is the molecular determinant of side population (SP) 
phenotype: 
Goodell et al identified murine bone marrow cells having stem cell characteristics by 
their rapid efflux of the Hoechst 33342 (Goodell et al., 1996). When unpurified 
murine bone marrow cells were labelled with the membrane-permeating, DNA 
binding vital dye Hoechst 33342, a very small fraction of cells extrudes this dye via a 
membrane pump. Analysis of these cells on a flow cytometer equipped with an 
ultraviolet (UV) laser source permits detection of these cells; when Hoechst-stained 
cells are analysed simultaneously through blue and red emission filters, the SP 
forms a dim tail extending from the normal G1 cell populations. These cells can 
reconstitute the bone marrow of lethally irradiated mice even when injected in low 
numbers, indicating that the SP cells are enriched for totipotent stem cells (Goodell 
et al., 1996). High levels of ABCG2 transcripts in SP cells from various sources and 
induction of SP phenotype by expression of ABCG2 indicate that ABCG2 is the 
molecular determinant of SP (Zhou et al., 2001) (fig 1.10). Specific inhibitors of 
ABCG2 abrogate the SP phenotype. Abcg2 -/- (Bcrp1 -/-) mice had significant defect 
in the SP compartment in bone marrow and skeletal muscle cells (Zhou et al., 2002).  
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Figure 1.10 ABCG2 is the molecular determinant of SP. RT-PCR analyses for Bcrp1/ABCG2 
expression in sorted SP cells from rhesus monkey bone marrow(a), mouse skeletal muscle (b) and 
murine ES cells (c) demonstrating that ABCG2 is the molecular determinant of SP (Zhou et al., 2001). 
1.2.7 ABCG2 in stem cells:  
Expression of ABCG2 is highly conserved in primitive stem cells from a variety of 
sources suggesting its role in the regulation of stem cell biology. In the 
haematopoietic compartment ABCG2 expression is restricted to the most immature 
haematopoietic progenitors in bone marrow and is sharply down-regulated at the 
committed progenitor level, suggesting an important role of this ABC transporter in 
the earliest stages of haematopoietic development (Scharenberg et al., 2002). The 
enforced expression of MDR1 (ABCB1) has been shown to cause stem cell 
expansion and an associated myeloproliferative syndrome in recipient mice. This 
indicates endogenously expressed transporters might be conferring functional effects 
in stem cells. The expression of human ABCG2 in mouse bone marrow cells 
expanded the SP population, and caused a reduction in the mature cell numbers, 
suggesting that ABCG2 is both a stem cell marker and an important determinant of 
the SP phenotype (Zhou et al., 2002). Expression of murine Abcg2 was 
demonstrated in CD34+/CD45- murine myogenic-endothelial progenitors, which are 
resident in the interstitial spaces of mammalian skeletal muscle (Tamaki et al., 
2002). ABCG2 expression has also been demonstrated in the multipotent progenitor 
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cells in the islets isolated form adult human pancreas (Lechner et al., 2002). 
Recently Du et al, reported the presence of an ABCG2 expressing population of cells 
in human corneal stroma that can be isolated as a side population with Hoechst 
labelling. These SP cells are clonogenic, lack expression of differentiated corneal 
cells or fibroblasts, could be induced to express differentiation markers of corneal 
keratocytes and markers of chondrogenesis and neural cells (Du et al., 2005). 
ABCG2-expressing side-population cells have been reported by several other groups 
to display the ability to express differentiated markers of multiple tissues in response 
to different environmental stimuli (Cai et al., 2004; Hierlihy et al., 2002; Jiang et al., 
2002; Lechner et al., 2002; Scharenberg et al., 2002; Suva et al., 2004; Zhou et al., 
2001). Although ABCG2 is clearly a stem cell specific gene, its physiological function 
in these cells is not yet clear. A possible function of ABCG2 in stem cell 
differentiation and protection against toxins is being investigated.   
1.2.8 Expression of ABCG2 in human cancers and the concept of 
cancer stem cells 
Doyle et al were the first to describe ABCG2 as a novel multidrug resistance 
transporter, overexpressed in drug selected breast cancer cell lines (Doyle et al., 
1998). Using monoclonal antibody BXP-21, ABCG2 has been demonstrated in over 
40% of 21 different types of solid tumors tested (Diestra et al., 2002). Since ABCG2 
has been demonstrated to transport various anti-cancer agents, most of the studies 
of ABCG2 expression in human cancers have focussed on its prognostic impact and 
the use of ABCG2 inhibitors that can effectively reverse chemotherapy resistance. 
Ross et al examined blast cells from 21 acute leukaemia patients (ALL: 1 patient, 
AML: 20 patients) for ABCG2 expression with quantitative RT-PCR. Blast cells in 
seven patients with high clinical drug-resistance disease had relatively high 
expression of ABCG2 mRNA. ABCG2 expression was low or barely detectable in 
blast cells from the remaining 14 patients (Ross et al., 2000). An additional study on 
ABCG2 mRNA expression, using 20 paired clinical AML samples from diagnosis and 
relapse or refractory disease, demonstrated that ABCG2 was the only drug 
resistance protein that was expressed at a significantly higher RNA level (median 
1.7-fold, P=0.04) in the relapsed/refractory state relative to that at diagnosis (van den 
Heuvel-Eibrink MM et al., 2002), suggesting that ABCG2 may be involved in 
resistance to one of the agents commonly used in front-line treatment of AML. An 
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upregulation of ABCG2 mRNA at relapse was also observed by another group, who 
studied 59 samples of children with newly diagnosed AML, of which 9 were also 
analysed in relapse. The median ABCG2 expression was more than 10 times higher 
in patients who did not achieve remission after the first chemotherapy course versus 
patients who did achieve remission (Steinbach et al., 2002). ABCG2 may also play a 
role in treatment failure in acute lymphoblastic leukemia (ALL), since ALL patients 
are treated with ABCG2 substrates such as methotrexate, daunorubicin, doxorubicin 
and mitoxantrone. ABCG2 is expressed and is functionally active in B-lineage ALL, 
and at lower levels in T-lineage ALL indicating that ABCG2 plays a small role in drug 
resistance in B-ALL (Stam et al., 2004). 
ABCG2 expression in tumor cells may also be demonstrated with the help of SP 
cells as ABCG2 is the primary determinant of SP. Since tumors contain cells that are 
heterogeneous in phenotype and proliferative potential, it could be reasoned that 
they might harbour SP cells, whose intrinsic dye efflux properties would be expected 
to be associated with the ability to export many cytotoxic drugs, hence leading to 
treatment failure or the risk of early relapse. The SP cells from human primary 
tumours have characteristics that support their consideration as “primitive” cells. 
Both stem cells and cancer cells are thought to be capable of unlimited proliferation. 
It has been observed that even in long-term cultured cancer cells, in general, 
sufficient numbers of cells  have to be injected to initiate an orthotopic tumor in 
recipient animals (Passegue et al., 2003), suggesting that in long-term tumor cell 
cultures not all cells are equal and only a small population of cells is tumorigenic. 
There is accumulating evidence that cancers, like normal organs, may be maintained 
by a hierarchical organisation that includes stem-like cells (SLC), precursor cells, 
and differentiated cells (Reya et al., 2001; Tu et al., 2002). The stem-like cells that 
feed the bulk cancer cells have been termed as cancer stem cells (CSCs). Most of 
these tumorigenic SLCs were identified using markers that identify putative normal 
stem cells. Interestingly, SLCs have also been identified in immortalized cell lines 
(Benchaouir et al., 2004), long-term cultured cancer cells (Hirschmann-Jax et al., 
2004; Kondo et al., 2004) or patient samples (Hirschmann-Jax et al., 2004) using the 
side population  technique.  
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Figure 1.11 Role of cancer stem cells in malignancy.  Cancer stem cells are thought to arise from 
either stem cells or some specific cells, which can revert to stem cells. The cancer stem cells self-
renew, generate cancer cells and form huge malignant tumors. Small cell aggregates containing 
cancer stem cells transfer through blood vessels, invade into other tissues, and form metastatic 
tumors. Both anti-cancer drugs and irradiation cause cancer cells to die by apoptosis, however cancer 
stem cells might survive and regenerate cancer. (Adapted from Takao Setoguchi, Cell Cycle 2004). 
 
Efforts to demonstrate the functional properties of SP in AML have revealed the 
heterogeneous nature of SP cells in terms of expression of known haematopoietic 
markers (Feuring-Buske and Hogge, 2001; Wulf et al., 2001). The concept of CSCs 
within the malignant SP cells has been strengthened by the following studies:  Wulf 
et al detected a malignant CD45+ CD34 low/neg SP cell subset in more than 80% of the 
AML patients studied. These cells generated CD45+ CD34+ malignant 
haematopoietic stem cells as well as committed myeloid progenitors (Wulf et al., 
2001). A much more detail study based on Hoechst 33342 SP phenotype, performed 
by Feuring-Buske et al, demonstrated the presence of normal progenitors within the 
SP+ CD34+CD38- compartment of samples from AML patients. When SP+ cells were 
sorted according to their expression of CD34 and CD38 markers, CD34+CD38- cells 
from 9 out of 15 AML samples were entirely cytogenetically normal, as were most 
CFC, LTC-IC and SRC from this population. In contrast, leukemic cells were 
detected among SP+ CD34-CD38- and among CD34+CD38- cells outside the side 
population (Feuring-Buske and Hogge, 2001), demonstrating that CSCs can be 
located within a subset of SP, and that SP alone is perhaps not a sufficient marker 
for the tumorigenic stem-like cells in cancers.  
In this study we have made an effort to elucidate the functions of ABCG2 in HSC. 
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2 Aim of the study. 
 
HSC are required to repopulate all blood cell lineages throughout the lifespan of an 
individual. This process of blood formation requires both stem cell divisions that 
produce lineage committed progenitors, and self renewal divisions that maintain 
stem cell pool in vivo. The cellular controls that regulate these decisions remain 
largely unknown, and are a major focus in the field of haematopoietic research. The 
expression of ABC proteins and their ability to transport Hoechst and Rhodamine 
dye as well as a number of chemotherapeutic drugs is another important feature 
observed in HSC. The expression pattern of the ABCG2 and the related ABC 
transporter MDR1 is stem cell associated. The overexpression of human MDR1 in 
murine BM resulted in HSC expansion and a myeloproliferative disorder in mice. 
Enforced expression of human ABCG2 in murine BM cells significantly blocked 
haematopoietic development (Zhou et al., 2001). These studies collectively suggest 
a role for ABCG2 in early haematopoiesis. However, till date there is no study 
demonstrating the role of ABCG2 in normal human haematopoiesis.  
The aim of the current study is to understand the biological role of ABCG2 in 
primitive human haematopoiesis. In this regard we have tried to address the 
following specific questions: 
• Does the constitutive expression of ABCG2 induce an abnormal proliferation 
or differentiation block as the MDR1? 
• What are the effects of constitutive expression of ABCG2 in haematopoietic 
stem cells at the level of the stem cell and early progenitors? 
To answer these questions, we have used a retroviral gene transfer approach to 
constitutively express ABCG2 in candidate human HSC.
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3 Materials & Methods 
3.1 Materials 
3.1.1 Plasmids 
MSCV-IRES-YFP: A modified form of the MSCV vector that contains a bicistronic 
EYFP expression cassette with an internal ribosomal entry site (IRES) from the 
encephalomyocarditis virus (ECM). This vector (called MIY) was kindly provided by 
Keith Humphries (Terry Fox Laboratory, Vancouver, Canada). 
 
ABCG2: Human ABCG2 gene was purchased from the RZPD, Deutsches 
Ressourcenzentrum für Genomforschung GmbH, Berlin, Germany. 
3.1.2 Antibodies 
ABCG2: Monoclonal antibody against human ABCG2 (Clone BXP-21) was 
purchased from Kamiya Biomedical Company, Seattle, WA. 
 
Goat anti-mouse: PE conjugated goat anti-mouse secondary antibody was 
purchased from R & D Systems GmBH, Germany 
 
Table 3.1 Antibody combinations used to study the transplanted human cells in NOD/SCID 
mice. 
No. Antibodies Target 
PE conjugated 
1 CD45 Lymphocytes 
2 CD34 HSC 
3 CD33 Myeloid 
4 CD15 Neutrophils & Eosinophils 
5 Glyco A Mature erythroid cells 
6 CD41a Megkaryocytes 
7 CD 117 HSC 
8 CD16 NK Cells 
9 Isotype Control 
APC conjugated 
10 CD71 Lympocytes/erythroid precursors 
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11 CD38 Haematopoietic progenitors 
12 CD19 B-cells 
13 CD36 Early erythroid cells 
14 CD56 NK Cells 
15 CD133 HSC 
16 Isotype Control 
3.1.3 Primers 
Oligonucleotide Sequence 5’ to 3’ 
ABCG2 forward ATTGAAGGCAAAGGCAGATG 
ABCG2 reverse TGAGTCCTGGGCAGAAGTTT 
β-ACTIN forward CTTCAACACCCCAGCCAT 
β-ACTIN reverse TAATGTCACGCACGATTTCC 
3.1.4 Mammalian cell lines 
Phoenix Ampho: Packaging cell line is used for transient, episomal stable, and 
library generation for retroviral gene transfer experiments (Stanford University, 
Medical Centre, USA). 
 
PG13: PG13 is a mouse embryonic fibroblast used as a retroviral packaging cell line. 
It was purchased from ATCC. Introduction of retroviral vectors into PG13 cells 
results in the production of retrovirus virions capable of infecting cells from many 
species excluding mice. 
 
K562: An erythroleukemia cell line derived from a chronic myeloid leukemia patient 
in blast crisis. K562 cells were purchased from ATCC. 
 
M2-10B4 j-GCSF-tkneo j-IL-3-hytk: Murine M2-10B4 fibroblasts engineered to 
produce high levels of both human granulocyte colony-stimulating factor (G-CSF) 
and interleukin-3 (IL-3; 190 and 4 ng/mll, respectively), referred henceforth as M2-
10B4 G-CSF / IL-3, were provided courteously provided by Connie Eaves (Terry Fox 
Laboratory, Vancouver, Canada).  
 
Sl/Sl j-SF-tkneo j-IL-3-hytk: SI/SI fibroblasts engineered to produce high levels of 
soluble Steel factor (SF), with or without production of the transmembrane form of 
SF (60 and 4 ng/ ml, respectively), referred henceforth as Sl/Sl SF / IL-3, were 
provided kindly by Connie Eaves (Terry Fox Laboratory, Vancouver, Canada). 
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3.1.5 Bacterial strain 
• E. coli DH5α 
3.1.6 The NOD-SCID Mice: 
The NOD/LtSz-scid strain was generated by crossing the SCID mutation from C.B-
17- scid mice onto the NOD background. C.B-17-scid mice lack functional T & B 
lymphocytes. The NOD strain mouse is an animal model of spontaneous 
autoimmune T-cell mediated insulin dependent diabetes mellitus (IDDM); however 
they have multiple defects in innate immunity. They are deficient in NK cell activity; 
display defects in myeloid development and function, and cannot generate either the 
classical or alternative pathways of haemolytic complement activation. The 
NOD/LtSz-scid lacks an adaptive immune system; due to the absence of T cells, 
they do not develop autoimmune IDDM and remain insulitis- and diabetes free 
throughout life. However they carry the innate immune defects present in the 
parental NOD/Lt stock of mice (Lowry et al., 1996). NOD/SCID mice were bred from 
the breeding pairs originally obtained from Taconic Europe and maintained in the 
animal facility located at the GSF-Haematology, Munich. All animals were handled 
under sterile conditions and maintained under micro isolators. 
3.1.7 Mice related reagents and equipment: 
Avertin solution: Stock solution was prepared by adding 15.5 ml tert-amyl alcohol 
to 25 grams Avertin (2-2-2 Tribromoethanol), both procured from Sigma-Aldrich, St. 
Louis, MO and dissolved overnight. For working solution, 0.5 ml stock solution was 
added to 39.5 ml of cell culture grade phosphate buffered saline (PBS) and dissolved 
with a magnetic stirrer.  
 
Formalin: 10% solution of formaldehyde from Sigma-Aldrich, St. Louis, MO in water 
was used for fixing parts of animal tissues. 
 
Sterile Syringes: BD Plastipak 1 ml syringe (BD Biosciences, Palo Alto, CA) for 
injection of cells in mice and Kendall Monoject 3 ml syringes (Tyco Healthcare, UK) 
for bone marrow flushing and plating of CFC.  
 
Sterile needles:  0.5 x 25 mm for intra venous injection of cells in mice and 0.55 x 
25 mm (BD Microlance, Drogheda, Ireland) for bone marrow aspiration from living 
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mice and flushing of bone marrow from extracted bones. 16 X 1.5 inch needles for 
dispensing and plating Methocult (CFC) media (Stem Cell Technologies, Vancouver, 
Canada) 
 
Ammonium Chloride solution: For erythrocyte lysis 0.8% NH4Cl with 0.1 mM 
EDTA (Stem Cell Technologies, Vancouver, Canada) 
 
Heparinized capillaries:  (Microvette CB 300) plastic capillaries for collection of 
blood, containing 15 units (I.E) Lithium heparin per ml of blood (Sarstedt, Numbrecht, 
Germany) 
3.1.8 Commercial kits 
MACS CD34 and CD133 cell Isolation kits: CD34 and CD133 HSC were isolated 
from UCB using MACS kits from Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany.  
 
DNeasy mini kit: Genomic DNA extraction kit from small cell numbers purchased 
from Qiagen GmbH, Hilden, Germany. 
 
Small-scale plasmid preparation: GFX miniprep kit for isolation of plasmid DNA 
from bacteria purchased from Amersham Biosciences GmbH, Freiburg, Germany. 
 
Gel elution of DNA and PCR product or DNA cleanup: GFX gel elution and PCR 
purification kit for DNA elution from gels and clean up of PCRs purchased from 
Amersham Biosciences GmbH, Freiburg, Germany. 
 
Total RNA and genomic DNA isolation: Total RNA isolation reagent (TRIZOL) and 
Genomic DNA isolation reagent DNAZOL were purchased from Invitrogen, Carlsbad, 
CA. 
 
Molecular weight markers: Nucleic acid size standards, 1 kb and 100 bp ladder 
were purchased from New England Biolabs (NEB, Beverly, MA). 
 
Enzymes: T4 DNA ligase, Xho I, Eco RV, Eco RI, Hpa I, and Pme I were purchased 
from New England Biolabs (NEB, Beverly, MA) 
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RT and PCR: Platinum Taq DNA polymerase kit, ThermoScript RT-PCR kit and 
DNaseI DNA inactivating enzyme kit were purchased from Invitrogen, Carlsbad, CA  
 
Real time PCR kit: LightCycler FastStart DNA Master SYBR green I kit were 
purchased from Roche Diagnostics, Mannheim, Germany.  LightCycler Carousel, 
carousel centrifuge and the LightCycler data analysis software from Roche 
Diagnostics were used.  
3.1.9 Buffers and special medium 
All buffers were prepared in deionized water. 
TAE buffer: (for agarose gel electrophoresis) 
• Tris-HCl (pH 8.2)  40 mM 
• Acetic Acid   20 mM 
• EDTA (pH 7.6)  2 mM 
 
FACS buffer: 
• Phosphate buffered saline (PBS) 
• FBS      3% 
• Propidium Iodide    1 µg/ml 
MACS buffer: 
• PBS (pH 7.4) 
• FBS      3% 
• EDTA      2 mM 
Serum free medium (SFM): 
IMDM (with L-glutamine) supplemented with the following:     
• BIT 9500 (BSA, insulin and transferrin) 20% 
• 2-Mercaptoethanol    10-4 M 
• Low-density lipoproteins (LDL)  40 µg/ml 
Haematopoietic cell washing buffer: 
IMDM supplemented with 2% FBS was used for washing of haematopoietic cells. 
The same buffer was used as a medium for injection of cells in mice. 
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3.1.10 Microscopes 
• Axiovert 25 Inverted light microscope from Carl Zeiss, Germany, was used for 
normal visualization of cells in culture and for scoring colonies in CFC assays. 
• Axiostar upright light microscope from Carl Zeiss, Germany, was used for cell 
counting and visualisation of cytospin preparations. 
3.1.11 Fluorescence activated cell sorting and analysis 
BD FACS Vantage SE System from BD Biosciences, Palo Alto, CA was used for 
fluorescence activated cell sorting. BD FACS Calibur System was used for 
acquisition and analysis of fluorochrome labelled cells. 
3.1.12 Reagents 
No. Reagents Company 
1 Acetic acid  Sigma-Aldrich, Germany 
2 Agar Sigma-Aldrich, Germany 
3 Agarose Sigma-Aldrich, Germany 
4 Avertin Sigma-Aldrich, Germany 
5 BIT Stem Cell Technologies, Canada 
6 Bromphenolblue  Sigma-Aldrich, Germany 
7 BSA Sigma-Aldrich, Germany 
8 Calcium Chloride Sigma-Aldrich, Germany 
9 Cytofix (Cell fixation reagent) BD Pharmingen, Germany 
10 DMEM PAN Biotech, Germany 
11 DMSO Sigma-Aldrich, Germany 
12 Ethanol Sigma-Aldrich, Germany 
13 Ethidium Bromide Sigma-Aldrich, Germany 
14 Fetal Bovine Serum PAN Biotech, Germany 
15 Formaldehyde Sigma-Aldrich, Germany 
16 G-418 (Geneticin) GIBCO, Invitrogen Corporation,Germany  
17 HEPES GIBCO, Invitrogen Corporation,Germany  
18 HLTM (Myelocult H5100) Stem Cell Technologies, Canada 
19 Hydrocortisone (solucortef) Stem Cell Technologies, Canada 
20 IMDM GIBCO, Invitrogen Corporation, Germany 
21 Isopropanol Sigma-Aldrich, Germany 
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22 Methanol Sigma-Aldrich, Germany 
23 Methocult H4434 (Methylcellulose) Stem Cell Technologies, Canada 
24 Pancoll PAN Biotech, Germany 
25 PBS PAN Biotech, Germany 
26 Penicillin/Streptomycin GIBCO, Invitrogen Corporation, Germany 
27 Protamine sulfate Sigma-Aldrich, Germany 
28 RPMI PAN Biotech, Germany 
29 SDS Sigma-Aldrich, Germany 
30 SOC medium Peqlab, Germany 
31 Sodium Chloride Sigma-Aldrich, Germany 
32 Trypsin/EDTA GIBCO, Invitrogen Corporation, Germany 
33 β- Mercaptoethanol Sigma-Aldrich, Germany 
 
3.1.13 Cytokines 
No. Cytokine Company 
1 Flt-3-ligand PAN Biotech GmbH, Germany 
2 G-CSF  Immuno Tools, Germany 
3 IL3 ImmunoTools, Germany 
4 IL6 Tebu-bio, Germany 
5 SF Steel factor ImmunoTools, Germany 
 
3.1.14 Apparatus 
No. Apparatus Company 
1 Biophotometer Eppendorf, Germany 
2 Cell culture dishes (3, 6, 10, 15 cm) Sarstedt, Germany 
3 Cell culture pipettes (2, 5, 10, 25 ml) Corning Inc., NY 
4 Cell scrapers Sarstedt, Germany 
5 Cell strainers BD Biosciences, CA 
6 Centrifuge (5810R) Eppendorf, Germany 
7 Centrifuge (Megafuge1.0) Herraus, Germany 
8 CO2 Incubator UniEquip, Germany 
9 Cryotubes Nunc 
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10 Cytospin 2 Shandon apparatus Thermo Electron Corp., USA 
11 Cytospin filter cards Histocom AG, Switzerland 
12 Cytospin slides Marienfield, Germany 
13 PCR cycler Peqlab, Germany 
14 PCR soft tubes Biozyme, Germany 
15 Pipetteman Eppendorf, Germany 
16 Thermomixer Eppendorf, Germany 
17 UV transilluminator Vilber Lourmat, France 
18 Electrophoresis system-Horizontal Peqlab, Germany 
 
3.2 Methods 
3.2.1 Cell culture 
• PG13 cell lines were cultured in DMEM supplemented with 10% foetal bovine 
serum (FBS), 1% penicillin/streptomycin and 1% Glutamax at 37°C in 5% CO2 
atmosphere. 
• K562 cell were cultured in RPMI supplemented with 10% FBS, 1% 
penicillin/streptomycin at 37°C in 5% CO2 atmosphere. 
• Phoenix Ampho packaging cells were cultured in DMEM supplemented 15% 
FBS, 1% penicillin/streptomycin and 1% Glutamax at 37°C in 5% CO2 
atmosphere. 
• M2-10B4 j-GCSF-tkneo j-IL-3-hytk cells were cultured in RPMI supplemented 
with 10% FBS, 1% penicillin/streptomycin, the selection antibiotics G418 (0.4 
mg/ml) and Hygromycin B (0.06 mg/ml) at 37°C in 5% CO2 atmosphere.  
• Sl/Sl j-SF-tkneo j-IL-3-hytk cells were cultured in DMEM supplemented with 
15% FBS, 1% penicillin/streptomycin, the selection antibiotics G418 (0.8 
mg/ml) and Hygromycin B (0.125 mg/ml) at 37°C in 5% CO2 atmosphere 
3.2.2 Freezing of mammalian cells 
Cells grown to a confluency of 90-95% in 10 cm cell culture dishes were washed with 
warm PBS and trypsinized. Trypsinized cells were washed using their respective cell 
culture medium and pelleted down at 400 x g for 5 min. The pellets were 
resuspended in 0.9 ml FBS. DMSO was added drop wise to the cells in FBS to a 
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final concentration of 10%. Aliquots were transferred to cryotubes and stored in 
freezing containers at -80°C for 24 hours and transferred to liquid nitrogen for long 
term storage. 
3.2.3 Thawing of cells 
Frozen cryotubes were thawed in a water bath at 37°C and immediately transferred 
to a 15 ml tube. Warm 2 ml culture medium (DMEM or IMDM with 10%FBS) was 
added and mixed gently. This was followed by addition of 8 ml culture medium and 
centrifugation at 400 x g for 5 minutes. The cell pellet obtained is resuspended in 
culture medium and placed into culture dishes or flasks and placed in CO2 incubator. 
A small aliquot of cells were taken apart for cell counting. For thawing UCB 
mononuclear cells, DNase I was used (0.1 mg/ml) to prevent cell loss through 
clumping. 
3.2.4 ABCG2 cloning 
The full-length ABCG2 (2.2 Kb) was sub cloned as Hpa I fragment upstream of the 
IRES sequence linked to the gene encoding the enhanced yellow fluorescent protein 
(EYFP) in the MIY vector. The resultant vector (ABCG2-YFP) was used for the 
preparation of stable packaging cell lines. As a control, the MSCV vector carrying 
only the IRES yellow fluorescent protein cassette (YFP virus) was used (fig 3.1). 
High-titre, helper-free recombinant retrovirus was generated by first transfecting the 
Phoenix Ampho packaging cell line and subsequently transducing PG13 packaging 
cells. High-titre producer clones were isolated for each virus. 
 
 
 
LTR LTRYFPIRESABCG2
LTR LTRYFPIRES
ABCG2-YFP Virus
YFP Virus
 
Figure 3.1 Retroviral constructs. Schematic representation of the retroviral constructs used for 
transduction of UCB Lin- cells. 
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3.2.5 Developing high titre producer cell lines 
Phoenix Ampho cells cultured in DMEM with 10% fetal bovine serum were plated at 
2.5 x 106 cells per 10 cm plate one day before transfection. Medium was changed 4 
hours prior to transfection.  In a 5 ml tube 20 µg of plasmid DNA, 62.5 μl of 2M CaCl2 
and dH2O to make up to 500 μl were mixed together. 500 μl of 2x HBS was added 
drop wise to form a precipitate within the next few minutes. This mixture was then 
added to the cells drop wise. After about 12 hours, the medium was replaced with 
fresh medium to collect virus particles. The virus containing medium (VCM) was 
collected  after 24 hours, filtered trough 0.45 µm filter, supplemented with protamine 
sulphate to give a final concentration of 5 µg/ml, and layered on PG13 packaging 
cells for viral infection. After repeated infections (3-5 times), PG13 cells were allowed 
to express the YFP contained in the plasmid vector for a period of about 48 hours & 
then YFP expressing cells were sorted out using FACS and cultured for up to 2 
weeks. From these YFP+ PG13 cells, single cells were sorted into 96 well plates, 
expanded & viral production was titred using K562 cells. Individual YFP+ PG13 
clones were tested & the clone that was producing the highest viral titre was 
identified & used for infecting umbilical cord blood derived haematopoietic cells. 
3.2.6 Purification of human UCB CD133+ and CD34+ cells 
Density Gradient Centrifugation: 
Umbilical cord blood was collected in heparinised syringes according to institutional 
guidelines following normal full-term deliveries. Informed consent was obtained in all 
cases. Mononuclear cells (MNC) were separated using density gradient 
centrifugation. Fresh umbilical cord blood, not older than 12 hours, was diluted with 2 
volumes of PBS and layered over Pancoll. Usually 35 ml of diluted blood was 
layered over 15 ml Pancoll in a 50 ml conical tube. This was centrifuged at 400x g for 
30 minutes at 20°C in a swinging-bucket rotor without brakes. The upper layer was 
aspirated and discarded, leaving the interphase undisturbed. The interphase 
containing MNC such as lymphocytes, monocytes and thrombocytes was then 
transferred to a new 50 ml tube, washed twice with large volumes of PBS, and then 
counted before labelling with magnetic bead or fluorochrome conjugated antibodies. 
Magnetic Separation: 
CD133+ cell purification was conducted using MACS CD133 Cell Isolation Kit that 
uses positive selection method.  Cells were resuspended in a volume of 300 μl per 
108 cells, blocked with 100 μl of FcR Blocking Reagent and labelled with 100 μl of 
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CD133 Microbeads. When working with higher cell number, all the reagent volumes 
& the total volume was scaled up accordingly. This was followed by incubation for 30 
minutes at 4-8°C. Cells were then washed twice by adding 10x the labelling volume 
of buffer and centrifuged at 300 x g for 15 minutes.  The resultant cell pellet was then 
resuspended in 500 μl of MACS buffer and loaded into MS Column mounted on 
magnetic separator. The negative cells were allowed to pass through and the column 
was washed at least three times with 2 ml buffer. The column was then removed 
from the separator, placed on a collection tube, loaded with fresh buffer, and the 
magnetically labelled cells flushed out using the plunger. The magnetic separation 
was usually repeated to get a purity of more than 95%. Purified cells were then 
frozen in FBS with 10% DMSO and thawed when needed for pre-stimulation and 
transduction. 
FACS sorting: 
CD34+ cell enrichment was done either by MACS as done for CD133+ cells or by 
FACS. For separation by FACS, MNCs were thawed from frozen stocks or prepared 
freshly from UCB and labelled using anti CD34-PE antibody (100 μL per 108 cells), 
for 30 minutes on ice. Labelled cells were then washed twice with PBS, resuspended 
in FACS buffer and sorted.  The sorted cells with purity above 95% were used for 48 
hour pre-stimulation followed by transduction. 
3.2.7 Pre-stimulation and transduction of human cells 
Frozen CD133+ or CD34+ cells were thawed and briefly prestimulated before 
transduction: Cells at 2 × 105/ ml were cultured for 48 hours in serum-free medium 
(SFM), comprising of Iscoves modified Dulbecco medium (IMDM) supplemented with 
the serum substitute (BIT),10 4 M mercaptoethanol and 40 µg/ml low-density 
lipoproteins (LDL). Following recombinant human cytokines were added to the SFM: 
100 ng/ml Flt-3 ligand, 100 ng/ml steel factor (SCF), 20 ng/ml interleukin-3 (IL-3), 
20 ng/ml IL-6, and 20 ng/ml granulocyte colony-stimulating factor (G-CSF). After 
48 hours, cells were resuspended in filtered VCM supplemented with the same 
cytokine combination and plated on tissue culture dishes that were preloaded twice 
with VCM, each time for 30 minutes. Protamine sulphate (5 µg/ml) was added to 
enhance viral infection. This procedure was repeated on the next 2 consecutive days 
for a total of 3 infections. For in vitro studies, aliquots of these cells were transferred 
to fresh SFM plus the same additives and cytokines and then incubated for an 
additional 48 hours prior to being stained with PE-labelled anti-CD34 antibody and 
 41
Materials & Methods 
isolation of the YFP+/CD34+ cells on a FACSVantage (Becton Dickinson) sorter. For 
in vivo studies, transduced cells were injected into nonobese diabetic/severe 
combined immunodeficiency (NOD/SCID) mice after final transduction (< 6 hours 
after the last exposure to fresh VCM) without pre-selection (fig 3.2). 
CB Lin-
Prestimulation Transduction
0 2 4 6
Days
Retrovirus
Human SRC assayABCG2-YFP/YFP
FACS (Sorting of YFP+ CD34+ cells)
CFC assays
Secondary CFC assays
replating
Cell Proliferation LTC-IC LTC-IC LDA
CFC assay as read-out
CFC assay as read-out  
Figure 3.2 Experimental Plan. Human UCB derived CD133+ cells (CB Lin-) are prestimulated and 
retrovirally transduced with ABCG2-YFP and YFP alone (control) thrice. Transduced CB cells that 
express CD34 are sorted out using FACS and placed into various in vitro assays 2 days after the final 
transduction. For the SRC assay, cells are injected in the NOD/SCID mice without any preselection 6-
10 hours after the final transduction. 
3.2.8 Human CFC Assay 
Haematopoietic colony-forming cells (CFC) were assayed using methylcellulose-
based medium (MethoCult; H 4434) (fig 3.3). Required number of pre-aliquoted 
tubes of MethoCult medium was thawed overnight under refrigeration (2-8°C) or at 
room temperature. The cells were diluted with IMDM + 2% FBS to 10X the final 
concentration(s) required for plating. For a duplicate assay 0.3 ml of diluted cells was 
added to 3 ml MethoCult tube and the contents vortexed vigorously. After about 5 
minutes, 1.1 ml of cell: methylcellulose mixture was dispensed into 35 mm culture 
dishes using sterile a 3 ml syringe and16-gauge bunt-end needle. The 35 mm culture 
dishes were placed into 10 cm petri dish along with an extra 35 mm dish containing 
sterile water to maintain humidity and placed in a CO2 incubator at 37°C and >95% 
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humidity. CFC numbers were evaluated after an incubation period of 12-14 days and 
distinguished into following classes: 
Colony-forming unit-erythroid (CFU-E): Produces 1-2 cell clusters containing a 
total of 8-200 erythroblasts. A CFU-E consists of mature erythroid progenitors that 
require erythropoietin (EPO) for differentiation. 
Burst-forming unit-erythroid (BFU-E): Produces a colony containing >200 
erythroblasts in a single or multiple clusters. A BFU-E consists of more immature 
progenitors than CFU-E and require EPO and cytokines with burst-promoting activity 
such as Interleukin-3 (IL-3) and Stem Cell Factor (SCF) for optimal colony growth. 
Colony-forming unit-granulocyte, macrophage (CFU-GM): Produces a colony 
containing at least 20 granulocyte cells (CFU-G), macrophages (CFU-M) or cells of 
both lineages (CFU-GM). CFU-GM colonies arising from primitive progenitors may 
contain thousands of cells in single or multiple clusters. 
Colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte 
(CFU-GEMM): A multi-potential progenitor that produces a colony containing 
erythroblasts and cells of at least two other recognizable lineages. Due to their 
primitive nature, CFU-GEMM tend to produce large colonies of >500 cells. 
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FACS sorted YFP+ CD34+ cells
Cells added to MethoCult and vortexed
Cells dispensed into pre-tested petri dishes 
using syringe and blunt-end needle. 
Incubated for 14-16 days in humidified 
incubator at 37°C and 5% CO²
Counted and evaluated colony types using 
inverted microscope and gridded scoring 
dishes
 
Figure 3.3 CFC assay procedure diagram. Human haematopoietic CFC assay in methylcellulose 
media detects haematopoietic progenitors (Figure adapted from the Stem Cell Technologies 
Catalogue). 
 
 
 
Table 3.2 Progenitor cells and the corresponding colonies 
Colonies Progenitor cell
Granulocytes CFU-G
Macrophages CFU-M
Erythroid BFU-E
CFU-E
Megakaryocytes CFU-Meg
Eosinophils CFU-Eo
Granulocytes, Macrophages, Erythroid, Megakaryocytes CFU-GEMM
Mast cells CFU-mast
Fibroblasts CFU-F
 
3.2.9 Liquid expansion assay 
To set up liquid suspension cultures, transduced YFP+ CD34+ cells were placed in 
the same cytokine-supplemented serum-free medium described above (section 
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1.2.7) for a period of up to 5 weeks. Weekly half media exchange was performed by 
removing half of the cells and medium and replacing them with fresh cytokine 
supplemented SFM. Aliquots of cells were taken from the medium removed and 
placed in methylcellulose for clonogenic progenitor assay. The colonies were scored 
after 14 days.  
3.2.10  Human Long-Term Culture-Initiating Cell (LTC-IC) Assay 
The two engineered murine fibroblast cell lines M2-10B4 G-CSF / IL-3 (expressing 
human G-CSF and IL-3) and Sl/Sl SF / IL-3 (expressing human SF and IL-3), were 
grown in selection medium. A 1:1 mixture of the above mentioned cell lines, was 
irradiated at 8000 cGy, and plated in collagen coated tissue culture dishes (3.0 x 105 
cells) for more than 24 hours before the addition of test cells. For adding the test 
cells, the medium of the dishes was replaced with freshly prepared human long-term 
culture medium (HLTM; Myelocult H5100), containing the required concentration of 
test cells (1x 104 – 2x104), taking care not to disturb the underlying feeder cells. 
Hydrocortisone (Solucortef) was added to the HLTM to achieve a final concentration 
of 10-6 M.  The dishes were incubated in a CO2 incubator at 37°C. Weekly half of the 
HLTM and cells were replaced with freshly prepared HLTM. Following 5-6 weeks of 
incubation, LTC-IC cultures were harvested, including the adherent cells using 
Tyrpsin/EDTA. The harvested cells were washed twice, counted and re-plated in 
MethoCult for CFC assay. The CFC dishes were scored after 14-16 days. The 
number of LTC-IC present in the initial test cell suspension was calculated by 
dividing the total number of CFC detected in the culture by the average number of 
clonogenic progenitors per LTC-IC for the standard conditions used. Values may 
also be expressed as LTC-IC derived CFC per number of test cells.  
3.2.11 LTC-IC Limiting Dilution Analysis 
M2-10B4 G-CSF / IL-3 and Sl/Sl SF / IL-3 cells (1:1 mixture) were established in 96-
well flat-bottom culture plates at a density of 1.25 x 104 cells (fig 3.4). On the day of 
assay, HLTM was removed using multi-channel pipettor with sterile tips and 
discarded. The test cells were added to the wells in 0.2 ml of HLTM with solucortef. 
The number of cells seeded per well is indicated in table 3.3. LTC-IC cultures were 
incubated at 37°C in humidified incubator (>95%) with 5% CO2 in air for six weeks. 
For weekly half media exchanges, one half of the medium and cells were removed 
and replaced with HLTM for five weeks. 
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Table 3.3 Initial test cell concentrations taken for the LTC-IC limiting dilution analysis. 
Cell number per well Number of wells 
1 20 
10 20 
50 20 
200 20 
800 16 
3200 12 
12800 10 
 
To harvest the LTC-IC, the HLTM and non-adherent cells were removed from wells 
and place into individual 12x75 mm sterile tubes using a pipette and sterile tips. 
Single wells were harvested at a time to avoid cross contamination of samples. Wells 
were rinsed once with 0.2 ml PBS and added to tube. 0.1 ml Trypsin-EDTA was 
added to each well and incubated for 3 to 5 minutes and examined for detached 
cells. Once the adherent cells are detached, the wells are washed with more PBS 
and the medium collected in the appropriated tube. The wells are finally washed with 
0.2 ml IMDM containing 2% FBS and transferred to the appropriate tube. The tubes 
were centrifuged at 1200 rpm for 10 minutes and the supernatant removed without 
disturbing cell pellet. Approximately 0.1 ml of medium was left along with the cell 
pellet and vortexed. To this 1 ml of Methocult (H4435) methylcellulose medium was 
added and vortexed again.  Each tube (contents of one well) was plated individually 
into 35 mm petri dish with 1 ml syringe (without needles attached). Several dishes 
(6-8) were placed in a 15 cm petri-dish along with an additional 60 mm open dish 
containing 5 ml sterile water to maintain humidity. The dishes are incubated at 37°C 
in humidified incubator (>95%) with 5% CO2 in air for 12 to 16 days. Colonies were 
counted and a well scored as positive if one or more BFU-E, CFU-GM or CFU-
GEMM were detected or scored as negative if no colonies were present. The LTC-IC 
frequency in the test cell population was calculated from the proportion of negative 
wells (no CFC present) and the method of maximum likelihood. Statistical analysis 
was performed using L-Calc™ software for limiting dilution analyses. 
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Figure 3.4: Experimental plan for setting up limiting dilution analysis. 
3.2.12 B-cell progenitor assay 
B-cell progenitor activity was assessed by plating 2 x 104 YFP+CD34+ cells on murine 
MS-5 cells in RPMI 1640 with 10% fetal calf serum (FCS) and 5% human AB serum 
with either 50 ng/mL SF, 10 ng/mL IL-2, and 10 ng/mL IL-15 or with these same 
factors plus 10 ng/mL IL-7, 100 ng/mL FL, and 50 ng/mL thrombopoietin, conditions 
permissive for B-lymphoid development in addition to varying degrees of myeloid cell 
development. After 3 or 6 weeks, both adherent and nonadherent cells were 
collected and analyzed by FACS for the expression of CD34, CD38, myeloid (CD15, 
CD33), lymphoid (CD3, CD19, CD20), erythroid (glycophorin A [GlyA], CD71), and 
megakaryocytic (CD41) and natural killer (NK) cell (CD56) markers. 
3.2.13 Transplantation into NOD/SCID mice 
Seven to eight week old NOD/SCID mice were sublethally irradiated at 275 cGy one 
day before injection. 137Cs γ- irradiator was used. For transplantation, transduced 
cells were washed, counted, resuspended in PBS and injected into lateral tail vein of 
irradiated mice (300-400µL/mouse). Engraftments of transduced cells into mice were 
either studied by observing bone marrow aspirates at 3, 6 and 9 weeks or by 
sacrificing the mice at week 8.  
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Supra-vital BM aspirations: 
BM aspirations were done at weeks 3, 6 and 9. Mice were anesthetized by intra-
peritoneal injection of Avertin (0.4-0.75 mg/g in mice) and the medullary cavity of the 
femur was entered with a 25 gauge needle. The marrow was then aspirated by the 
syringe attached to the needle and subsequently transferred to a tube containing 
IMDM with 3% FCS and 0.2mM EDTA. This was followed by red cell removal & 
FACS staining. 
BM analysis: 
Mice were sacrificed according to the institutional guidelines. Hind limbs were 
removed from the animal and cleared of adhering muscles and other connective 
tissues. BM from the femurs and tibiae were flushed out using IMDM containing 10% 
FCS and 0.2mM EDTA. This was followed by red cell removal & FACS staining. 
FACS staining: 
The BM resuspended in IMDM (with 3% FCS, 0.2mM EDTA), was treated with 1% 
ammonium chloride solution (20 minutes on ice) for selective removal of red cells. 
The cells were washed, passed through a cell strainer (60 µ pore-size), and the 
viability was determined by trypan blue exclusion. Approximately 106 cells were 
resuspended in PBS (with 3% FBS) containing FcR blocking reagent and then 
divided into smaller aliquots for individual / batch staining with monoclonal antibodies 
indicated in table 3.1. 
3.2.14 Intracellular staining with ABCG2 antibody 
1x 106 cells were resuspended in 200 µl Cytofix to fix the cells, incubated for 20 
minutes at 4°C and washed twice with 1x Permwash buffer. The cells were 
centrifuged at 280 x g for 5 minutes. The pellet was resuspended in 50 µl of PBS and 
the primary antibody was added and incubated for 15 minutes at 4°C. After 
incubation, the cells were washed twice with 1x Permwash buffer, resuspended once 
again in 50 µl PBS, and stained with fluorochrome (PE) conjugated secondary 
antibody for 15 minutes at 4°C in dark. After staining, the cells were washed twice 
with 1x Permwash buffer and resuspended in 500 µl PBS and analysed using FACS 
Calibur. 
3.2.15 RNA and genomic DNA isolation and cDNA preparation 
The Trizol reagent method described by the manufacturer was used to extract RNA 
with the addition of 1 ml Trizol solution per million cells. Equal amounts of RNA as 
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quantified by a spectrophotometer were added to each reaction (in a set) used for 
cDNA preparation for the semiquantitative PCRs. Each sample was treated with 
DNaseI for prevention of genomic DNA contamination in cDNA samples. This was 
performed for each sample prior to cDNA preparation according to the 
manufacturer’s instructions.  
Genomic DNA was isolated from a minimum of 1x 106 BM cells for retroviral 
integration detection using the DNAZOL reagent and the protocol for the same 
according to the manufacturer. Genomic DNA was resuspended in sterile water and 
quantified using a spectrophotometer after proper dissolution. 
cDNA was prepared from DNaseI treated RNA. First-strand cDNA synthesis was 
done with ThermoScript kit. In a 20 μl reaction volume, 1 μg RNA and 1 μg of oligo 
(dT) were mixed to a final volume of 11 μl and incubated 10 minutes at 70°C. Then, 
4 μl of 5 X first-strand buffer, 2 μl of DTT 0.1 mol/L, 1 μl of 10 mmol/L 
deoxynucleoside triphosphate mix, and 2 μl of ThermoScript reverse transcriptase 
were added. The sample was incubated 1 hour at 42°C and used for PCRs. 
3.2.16 LM-PCR for detection of retroviral integration site 
For the linker-mediated PCR (LM-PCR), integrated long-terminal repeats (LTRs) and 
flanking genomic sequences were amplified and then isolated using a modification of 
the bubble LM-PCR strategy (42, 43). Aliquots of the cell lysates from leukemic mice 
were digested with PstI or Ase (New England Biolabs Inc.), and the fragments were 
ligated overnight at room temperature to a double-stranded bubble linker(5′-
CTCTCCCTTCTCGAATCGTAACCGTTCGTACGAGAATCGCTGTCCTCTCCTTG- 
3′ and 5′-ANTCAAGGAGAGGACGCTGTCTGTCGAAGGTAAGGAACGGACGAG 
AGAAGGGAGAG- 3′). Next, a first PCR (PCR-A) was performed on 10 μl (one-
tenth) of the ligation product using a linkerspecific Vectorette primer (5′-
CGAATCGTAACCGTTCGTACGAGAATCGCT- 3′) (Invitrogen Corp.)and an LTR-
specific primer (LTR-A: 5′-CAACACACACATTGAAGCACTCAAGGCAAG-3′) under 
the following conditions: 1 cycle of 94°C for 2 minutes, 20 cycles of 94°C for 30 
seconds and 65°C for 1 minute, and 1 cycle of 72°C for 2 minutes. The bubble linker 
contains a 30-nucleotide nonhomologous sequence in the middle region that 
prevents binding of the linker primer in the absence of the minus strand generated by 
the LTR-specific primer. A 1-μl aliquot of the PCR-A reaction (one fifteenth) was then 
used as a template for a second nested PCR (PCR-B) using an internal LTR-specific 
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primer (LTR-B: 5′-GAGAGCTCCCAGGCTCAGATCTGGTCTAAC-3′) and the same 
linker-specific Vectorette primer as was used in PCR-A, with the following conditions: 
1 cycle of 94°C for 2 minutes, 30 cycles of 94°C for 60 seconds and 72°C for 1 
minute, and 1 cycle of 72°C for 2 minutes. Ten microliters (one-half) of the final PCR-
B product was electrophoresed using 2% agarose tris-acetate- EDTA gel. Individual 
bands were excised and purified using the QIAEX II Gel Extraction Kit (QIAGEN) 
and then cloned into PCR2.1 (Invitrogen Corp.) before sequencing of the integration 
site of the retrovirus. 
 
Results 
 
4 Results 
4.1 Isolation of human UCB CD133+ cells 
Human umbilical cord blood is a relevant source of CD133+ haematopoietic cells.  
CD133+ cells (>95%) co-express the CD34 antigen, where as an average of 85 
percent of CD34+ cells co-expressed CD133 in UCB samples (Bonanno et al., 2004). 
UCB samples were collected and processed to deplete RBCs and subsequently 
immunoselected using microbead-conjugated anti-CD133 MoAb (Miltenyi Biotech). 
The mean volume of the initial UCB samples collected was 13.5 ml / donor (range, 5-
35 ml). Isolation using MACS procedures yielded an absolute amount of 2.0 x 105 
CD133+ cells (range, 0.9-22). The enriched samples had an average CD133+ cell 
frequency of 92.04 percent (range, 73-100). Enriched samples were also analysed 
for the expression of CD34 antigen. More than 95% of the CD133+ isolated cells 
coexpressed the CD34 antigen. 
97.85 %
 
Figure 4.1 Representative dot plot analysis of the CD34 and CD38 markers on MACS-isolated 
CD133+ cells. 
 51
Results 
4.2 Efficient retroviral transduction of ABCG2 in human 
haematopoietic cells 
In order to track the retrovirally transduced cells by FACS, the bi-cistronic vector 
containing ABCG2 upstream of an IRES element and an YFP reporter gene was 
constructed in the MSCV viral backbone (ABCG2-YFP) as described in the methods 
section. The analogous vector containing YFP alone was used as a control (fig 4.2). 
Gene delivery efficiencies were determined by measuring the EYFP fluorescence 48 
hours after the final transduction round. Twenty three percent (± 5%) and 54% (± 
4%) of Lin- cord blood cells exposed to ABCG2-YFP VCM or the YFP VCM, 
respectively, were found to be YFP+ when examined by FACS, demonstrating high 
efficiency of gene transfer by both vectors. The CB cells were also analysed for the 
expression of CD34 marker after transduction. The overall percentage of CD34 
expressing cells in the transduced and non transduced compartments did not show 
any difference between ABCG2-YFP and YFP transduced cells. However, in the 
ABCG2-YFP transduced CB cells the proportion of YFP+ CD34+ cells were 2.3 fold 
less than the proportion of YFP+ CD34+ cells in the control vector transduced cells 
(n= 19; mean ABCG2-YFP+ CD34+ = 6.5%, mean YFP+ CD34+ = 15%). This 
difference is due to the 2.3 fold lower transduction efficiency of the ABCG2-YFP 
virus. 
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Figure 4.2 Gene transfer efficiencies. ABCG2-YFP and YFP (control) transduced CD133+ cells 
were analysed 48 hours after final transduction for the expression of YFP using FACS Calibur in order 
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to determine the gene transfer efficiency. Expression of CD34 marker was also analysed and used for 
sorting out CD34+ YFP+ cells that were used subsequently in different in vitro assays. Although the 
proportion of total CD34+ cells 2 days after transduction did not differ between the cells transduced 
with either vectors, the number of transduced CD34+ cells expressing ABCG2-YFP was 2.4 fold lower 
than those expressing YFP vector. Values represent the mean (± s.e.m.) from 19 independent 
experiments.   
4.3 Assessment of ABCG2 overexpression in retrovirally 
transduced cells 
To determine whether the transduced cells properly expressed ABCG2, 
immunodetection was performed using flow cytometry. K562 cells transduced with 
ABCG2 (K562-ABCG2) and with YFP vector control (K562-YFP) were stained using 
anti-ABCG2 antibody BXP-21 (fig 4.3). PE conjugated goat anti-mouse antibody was 
used to secondarily label the BXP-21 antibody. ABCG2 protein was clearly 
recognized in K562 cells transduced with ABCG2-virus but not in those transduced 
with YFP control vector.  
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Figure 4.3 ABCG2 protein expression analysis. K562 cells were transduced with ABCG2-YFP 
virus (K562-ABCG2) or YFP control virus (K562-YFP) in the same manner as the UCB Lin- cells. After 
48 hours, transduced cells were fixed and permeabilized and stained using anti-ABCG2 antibody. A 
PE labelled secondary antibody (Goat anti-mouse Ab) was used to detect ABCG2 positive cells by 
FACS Calibur. 
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4.4 Constitutive expression of ABCG2 increases the production 
of CFC in vitro 
Clonogenic haematopoietic assays detect progenitor cells committed to a specific 
lineage by seeding candidate populations into semi-solid methylcellulose media. 
Progenitors identified by this assay are retrospectively classified as colony forming 
cells (CFC) and can be quantitatively subdivided into lineage restricted subtypes by 
examining the composition of the resulting progeny (described in the methods 
section). UCB cells transduced with ABCG2-YFP or YFP vectors were sorted 48 
hours after transduction for CD34+ YFP+ cells and placed in standard methylcellulose 
assays for evaluation of clonogenic haematopoietic progenitor cells. Primary CFC 
assay was readout after 14 days. Both YFP infected cells as well as ABCG2-YFP 
infected cells formed normal colonies in the CFC assays and did not show abnormal 
blasts (fig 4.4 shows the formation of normal colonies by ABCG2-YFP infected cells). 
However, there was a 1.6 fold increase in the mean absolute number of colonies 
generated by ABCG2-YFP infected cells as compared to YFP infected cells (fig 4.5). 
This increase in the total number of CFC generated was due to an increase in the 
colony formation by CFU-GEMM, CFU-GM and BFU-E. ABCG2-YFP transduced 
cells showed a modest 2.1-fold higher number of CFU-GEMM colonies than in the 
YFP controls (n = 12; P < 0.002; ABCG2-YFP mean = 46.04, YFP mean = 21.93). 
The number of CFU-GM colonies generated by the ABCG2-YFP cells was 1.5-fold 
higher than in the YFP controls (ABCG2-YFP mean = 50.5, YFP mean = 32.75). The 
erythroid burst-forming units (BFU-E) were 1.7 fold higher in the ABCG2-YFP cells 
as compared to the YFP controls (ABCG2 mean =50.83, YFP mean = 29.25). No 
difference was observed in the number of CFU-M colonies between the ABCG2-YFP 
and control vector transduced cells. 
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Figure 4.4  Representative photomicrographs of colonies generated by ABCG2 transduced Lin- 
cells.  ABCG2 infected UCB Lin- cells generated normal colonies from CFU-GM, CFU-M, CFU-
GEMM and BFU-E. Methylcellulose dishes were observed under light and fluorescent microscopes: 
On the left panel are shown the light micrographs of colonies and the right panel depict fluorescence 
micrographs of the same colonies showing the expression of YFP (50 X magnification). 
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Figure 4.5 Colonies derived from ABCG2–YFP- and YFP-transduced progenitors. Umbilical cord 
blood derived CD34+ cells were transduced with ABCG2-YFP or YFP vector and plated in 
methylcellulose CFC assays. Results are shown as the frequency and distribution of colonies scored 
on day 14. Bars represent mean (± s.e.m.) frequencies from 12 independent experiments performed 
with several different umbilical cord blood samples. Significance was determined by a paired 
Student’s t-test and is indicated above the respective bars. *P < 0.05, **P < 0.02, ***P < 0.002 
indicate statistically significant differences from the control. 
4.5 ABCG2 overexpression increases the replating potential of 
the CFC in vitro 
In order to detect the clonogenic potential of cells generated by the primary colonies, 
secondary CFC assays were performed. The methylcellulose dishes containing 
primary colonies were harvested, replated into fresh methylcellulose dishes and 
scored after 12-14 days (fig 4.6). 
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Figure 4.6 Secondary colony formation. Methylcellulose dishes of primary CFC cultures derived 
from ABCG2-YFP-and YFP-transduced progenitors were harvested on day 14, and the progenitor 
cells resuspended in IMDM 2% FBS were replated in secondary methylcellulose cultures. Secondary 
colony formation was assessed after 12-14 days. Mean values of secondary colony formation of 9 
independent experiments are indicated by bars(± s.e.m.). *P < 0.01 indicates statistically significant 
difference from the control. 
 
In the secondary CFC assays, ABCG2-YFP transduced cells generated 3 fold more 
total colonies as compared to the YFP transduced cells (n = 9; P < 0.01; ABCG2-
YFP mean = 111 colonies, YFP mean = 35 colonies / 1000 cells plated in the 
primary CFC assay).The ABCG2-YFP transduced progenitors generated 12 - fold 
more secondary erythroid colonies as compared to the YFP control (ABCG2-YFP 
mean = 36.5 colonies, YFP mean = 3.17 colonies / 1000 cells plated in the primary 
CFC assay). Moreover, the number of granulocyte and macrophage secondary 
colonies was found to be 2.4 fold higher in the ABCG2-YFP transduced cells as 
compared to the YFP control (n = 9; P < 0.03; ABCG2-YFP mean = 74.5, YFP mean 
= 32.0).  
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4.6 Constitutive expression of ABCG2 does not change the 
expansion kinetics of CD34+ cells 
In order to study the effects of constitutive expression of ABCG2 on the proliferative 
potential of progenitor cells, in vitro liquid expansion experiments were performed. 
YFP+ CD34+ cells were sorted from ABCG2-YFP and YFP transduced CD133+ cells 
and grown in SFM as described in methods section. Both ABCG2-YFP and YFP 
transduced cells showed similar growth kinetics and there was no proliferative 
advantage demonstrated by the ABCG2 transduced cells over the control arm (fig 
4.7). In order to check the relative numbers of clonogenic progenitors throughout the 
liquid expansion, we performed CFC assays from cells in liquid cultures at different 
time points (fig 4.8). Typical expansions generated an approximate 1000-fold 
increase in the content of progenitors by third week and did not differ significantly 
between ABCG2-YFP and YFP transduced cells.  
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Figure 4.7 Growth kinetics of ABCG2-YFP and YFP transduced CD34+ cells. In vitro expansion of 
UCB derived cells transduced with ABCG2-YFP and control (YFP) vectors and sorted for YFPP+ CD34+ 
cells. Twenty thousand sorted cells were cultured for upto a period of 5 weeks in SFM supplemented 
with 5-cytokine combination (rh FLT-3 ligand, SCF, IL-3, IL6 and G-CSF), with weekly half media 
change. Mean total cell counts (± SEM) performed weekly are shown here for the ABCG2-YFP and 
YFP transduced cells from 5 independent experiments. No significant difference in cell expansion was 
noted between these two arms. 
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Figure 4.8.  Expansion kinetics for progenitors in liquid expansion experiments. ABCG2-YFP 
and YFP transduced CD34+ cells were maintained in liquid suspension cultures as described in 
methods section. Cells were removed during the weekly half media change for clonogenic progenitor 
assays in methylcellulose. The progenitor population was found to expand at similar rates in cells with 
ABCG2-YFP and YFP expression. Mean fold expansion observed in 5 independent liquid culture 
experiments are represented here.  
4.7 Bulk LTC-IC assays demonstrate no increase in the output 
of the LTC-IC by overexpression of ABCG2 
In order to detect long-term culture-initiating cells (LTC-IC), 5 week long term 
cultures were performed with sorted ABCG2-YFP or YFP transduced UCB CD34+ 
cells. The CFC readout at the end of this assay was used for calculation of LTC-IC 
present at the time of seeding of cells. The data obtained from this assay is 
represented as the mean number of LTC-IC per 10,000 cells. The expression of 
ABCG2 did not increase the number of LTC-IC as compared to the control vector 
(data not shown).  To ascertain whether the constitutive expression of ABCG2 
produced any change in the frequency of LTC-IC, another set of experiments called 
the LTC-IC limiting dilution analysis (LTC-IC LDA) were performed.  
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4.8 LTC-IC limiting dilution analysis  
The LTC-IC limiting dilution analyses (LTC-IC LDA) were performed as described in 
the methods section. The CFC assay performed at the end of supported culture was 
scored after 14-16 days. Individual dishes were quantified as either positive or 
negative for the presence of colonies (table 4.1). Additionally, in one of the two 
independent LTC-IC LDA experiments, each positive dish was analysed in detail and 
colonies were classified. The frequencies of LTC-IC obtained in two independent 
experiments are indicated in table 4.2. The expression of ABCG2 did not change the 
frequencies of LTC-IC as compared to the control arm. In order to investigate the 
clonogenic potential of the LTC-IC, the detailed observation of the kind of colonies 
generated was performed (fig 4.10). 
 
Table 4.1 Results from two LTC-IC LDA: In each experiment several dilutions of transduced CB 
cells were plated (doses). Each dilution had several iterations as indicated here. The percentage 
negative wells observed are indicated in the table. 
% negative wells in 
experiment no. 1 
% negative wells in 
experiment no. 2 
Dose 
(Cells/well) 
Iteration 
YFP ABCG2-YFP YFP ABCG2-YFP 
1 20 95 95 100 100 
10 20 95 100 100 100 
50 20 75 80 90 90 
200 20 55 60 78.95 89.47 
800 16 50 18.75 68.75 50 
3200 12 25 60 87.50 57.14 
12800 10 16.67 14.29 50 62.5 
 
Table 4.2 LTC-IC frequencies obtained from LTC-IC LDA. 
LTC-IC frequency  
Exp no. 1 Exp no. 2 
ABCG2-YFP 1 in 1595 1 in 6227 
YFP 1 in 1366 1 in 5197 
Results 
 
0.01
0.1
1
10
100
CFU-GEMM CFU-G/M/GM BFU-E Total CFC
YFP
ABCG2-YFP
CFC type
N
o.
 o
f C
FC
 p
er
 L
TC
-IC
N
o.
 o
f C
FC
 p
er
 L
TC
-IC
 
Figure 4.9 LTC-IC derived CFC. Colonies derived from LTC-IC limiting dilution analyses classified 
according to their morphology. In one of the LTC-IC assay, detail analysis of the types of CFC 
generated from the LTC-IC was performed. 
 
There was an increase in the number of colonies derived from CFU-GEMM by 2.6 
folds in the ABCG2-YFP arm as compared to the YFP arm (ABCG2-YFP mean = 
0.4, YFP mean = 0.15 CFC per LTC-IC). An increase of 10.6 fold in the colonies 
derived from CFU-G, GM and M together was observed in the ABCG2-YFP arm as 
compared to the YFP arm (ABCG2-YFP mean = 5, YFP mean = 0.47 CFC per LTC-
IC). There was only a meagre increase of 1.2 fold in the BFU-E colonies formed in 
the ABCG2-YFP arm as compared to the YFP control. The total CFC number that 
comprises of all kinds of colonies observed was found to be 7 fold higher in the 
ABCG2-YFP arm as compared to the YFP arm (ABCG2-YFP mean = 8.7, YFP mean 
= 1.2). All these data suggest that even though transduction of ABCG2 did not 
change the frequency of LTC-IC, it was able to positively influence the colony 
formation ability of the LTC-IC. In order to further investigate the effects of 
constitutive expression of ABCG2 on haematopoietic stem cells, transplantation 
studies in the NOD/SCID model was performed. 
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4.9 Multilineage differentiation of ABCG2-transduced human 
CB cells in NOD/SCID mice 
In order to evaluate the effects of ABCG2 on the growth potential of human 
haematopoietic stem cells in the NOD/SCID mice, xeno-transplantations were 
performed. Irradiated NOD/SCID mice were transplanted with the unselected 
progeny of 3-5 x 105 CD133+ cells 4-6 hours after their final exposure to ABCG2-
YFP or YFP (control) VCM. In vitro analyses for gene transfer and CD34 expression 
indicated that 6.5 ± 2 % and 15 ± 6% of the CD34 expressing cells have been 
transduced with ABCG2-YFP or YFP VCM respectively, (i.e. % of YFP+ cells 2 days 
post-transplantation that were CD34+). The difference in these values is consistent 
with the 2.3 fold difference in the titres of ABCG2-YFP and the YFP VCM used in 
these experiments. The mice were analysed for engraftment of human SCID 
repopulating cells (SRC) 8 weeks post transplantation. In order to detect SRC, 
multilineage differentiation of the transplanted CD34+ YFP+ cells was examined in 
the NOD/SCID mice (table 4.3) Multilineage cells were detected in human CD45+ 
YFP+ cells from BM of ABCG2-YFP-SRC and YFP-SRC transplanted mice. These 
findings revealed that ABCG2 transduced CB cells contain normal SRC that are able 
to repopulate the NOD/SCID mice. 
 
Table 4.3 Multilineage engraftment generated by ABCG2-transduced human CB cells 
transplanted into immunodeficient mice. 
Multilineage engraftment 
Lymphoid Myeloid 
NOD/SCID mice 
8 weeks post-transplantation 
% CD19 % CD33 % CD15 % CD11b 
YFP (n = 4) 50 ± 4 51 ±5 25 ± 4 38 ± 4 
ABCG2-YFP (n = 4) 31 ± 7 71 ± 9 43 ± 10 62 ± 10 
 
4.10 Detailed phenotypic analysis of human CB cells in 
NOD/SCID mice 
To gain insight into the differentiation pattern of the ABCG2-transduced CB cells in 
immunodeficient mice, a detailed analysis of the human cells generated in the mice 
was performed. A panel of anti-human antibodies targeting different haematopoietic 
Results 
cells, described in the material section, was used in the study. All the engrafted 
NOD/SCID BM were analysed using this antibody panel and the results obtained are 
indicated in figure 4.11.  
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Figure 4.10 Output of human cells produced in the NOD/SCID mice transplanted with ABCG2-
transduced CB cells.  Detail analyses of the type of human cells produced in the NOD/SCID BM was 
performed 8 weeks post-transplantation. The data is represented in this figure as the mean (± SEM) 
percentage of total transduced human cells found in the BM of mice. *P < 0.05, **P < 0.01 indicate 
statistically significant differences from the control.  
 
A clear reduction in the proportion of CD19+(B-lymphoid) cells was observed in the 
ABCG2-transduced CB cells as compared to the YFP control (ABCG2-YFP mean = 
31%, YFP mean = 50% P < 0.05).  The ABCG2-YFP transduced CB cells showed a 
1.4 fold increase in the proportion of CD 33+ (myeloid) cells as compared to the YFP 
control (ABCG2-YFP mean = 71.5%, YFP mean = 51%, P < 0.05). The production of 
differentiated myeloid cells was further analysed using markers for all three major 
myeloid lineages. The proportion of granulocytic cells (CD15+) was found to be 
increased in the ABCG2-YFP transduced CB cells as compared to the YFP-
transduced cells (ABCG2-YFP mean = 43%, YFP mean = 25%).  The proportion of 
another type of late myeloid cells (CD11b+ cells) was also found to be increased on 
the expression of ABCG2-YFP in CB cells as compared to the YFP control (ABCG2-
YFP mean = 62%, YFP mean = 38%, P < 0.05). The generation of megakaryopoietic 
(CD41+) lineage showed no significant changes in ABCG2-YFP transduced cells as 
compared to the YFP transduced cells. The proportion of CD36 (found on platelets 
 63
Results 
 64
and their precursors, monocytes, but absent on adult erythroid cells) expressing cells 
also did not change significantly upon constitutive expression of ABCG2 in CB cells. 
The percentage output of CD16+ (Natural Killer) cells by the ABCG2-YFP transduced 
cells showed a 2.8 fold increase as compared to the output in the vector control cells 
(ABCG2-YFP mean = 25%, YFP mean = 8.8%). The most dramatic effect of ABCG2 
constitutive expression was notable in the output of erythroid cells. The production of 
glycophorin A+ (Gly A+) erythroid cells from ABCG2-YFP transduced CB cells 
showed a 3 fold increase over those produced from YFP transduced cells (ABCG2-
YFP mean = 15.3%, YFP mean = 5.1%, P < 0.006). This result is consistent with the 
increase in erythroid colonies in primary and secondary CFC assays demonstrated 
upon constitutive expression of ABCG2 in CB cells. Overall these results 
demonstrate that constitutive expression of ABCG2 increases most of the 
differentiated myeloid progeny of transduced CB cells in the NOD/SCID mice but 
there is a decrease in production of B-lymphoid progeny. This skewed 
haematopoietic engraftment pattern is described in the following section. 
4.11 Inversion of the lymphoid-myeloid ratio 
The production of mature progeny of transplanted CB lin- cells in the NOD/SCID 
mice is normally biased towards the lymphoid lineage and more B-lymphoid cells 
appear than myeloid cells (Glimm et al., 2001). Thus, the lymphoid-myeloid ratio is 
more than 1. In the recipients of ABCG2-YFP transduced CB cells, however, the 
number of CD19+ B-lymphoid cells generated was found to be 2.3 fold lower than 
those generated in the control mice (ABCG2-YFP mean = 5.6 x 105, YFP mean = 1.3 
x 106 cells, P < 0.05) (fig 4.12). 
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Figure 4.11 Comparison of absolute number of YFP+ CD19+ cells present in the BM of NOD/SCID 8 
weeks after transplantation with ABCG2-YFP and YFP (control) transduced CB cells. 
 
The significantly lowered number of CD19+ cells and the increase in myeloid cell 
numbers in the mice transplanted with ABCG2-YFP transduced CB cells led to an 
inversion of the lymphoid-myeloid ratio (fig 4.13) defined as the ratio between CD19+ 
and CD15+ cells (median ratios of ABCG2-YFP = 0.75, YFP = 2.22, P < 0.05). The 
lymphoid-myeloid ratio observed in the non-transduced cells of the same mice that 
contained ABCG2-YFP transduced cells was found to be normal (fig 4.13).  
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Figure 4.12 Inversion of lymphoid-myeloid ratio in the ABCG2-YFP transduced CB cells. Eight weeks 
post transplantation, the NOD/SCID mice BM were analysed for the presence of YFP+ CD19+ and 
YFP+ CD15+ cells. The median ratios of the total lymphoid and myeloid cells generated are shown in 
the figure (n = 5 in each arm).  
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4.12 Effect on HSC 
Our data suggest that overexpression of ABCG2 resulted in increased expansion or 
proliferation of SRC. In order to investigate this further, we analysed the engrafted 
NOD/SCID mice for the presence of primitive human haematopoietic cells. The 
NOD/SCID mice BM cells were stained with CD34 and CD38, and cKIT antibodies 
(fig 4.14). YFP+ cells expressing CD34 antigen were detected in both YFP and 
ABCG2-YFP transduced cells, however the proportion of CD34+ cells in the ABCG2 
mice was significantly higher than in the vector control (1.5 fold, ABCG2-YFP mean 
= 21.6%, YFP mean = 14.6%, P < 0.05). The CD34 cells were further analysed for 
the presence of early differentiation marker CD38. The proportion of cells expressing 
both CD34 and CD38 (CD34+ CD38+ cells) was also found to be increased in the 
mice transplanted with ABCG2-YFP transduced cells as compared to the vector 
control (1.5 fold, ABCG2-YFP mean = 18.8%, YFP mean = 12.6%). The percentage 
of cKIT+ cells (haematopoietic progenitors) showed a slight increase in the ABCG2 
mice (fold increase = 1.5, ABCG2-YFP mean = 9.3%, YFP mean = 6.2%).   
However, no difference was observed in the proportion of most primitive 
haematopoietic cells (CD34+ CD38-), comprising 0.81 and 0.83% of human cells in 
the BM of ABCG2-YFP and YFP mice respectively. These observations indicate that 
expression of ABCG2 in CB Lin- cells does not increase the number of human 
CD34+ CD38- most primitive cells in the NOD/SCID mice, but of more differentiated 
progenitors known to comprise the fraction of clonogenic progenitors  
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Figure 4.13 Comparative analysis of the expression of haematopoietic stem and progenitor cell 
markers in the YFP+ human cells derived from the NOD/SCID mice transplanted with ABCG2-YFP 
and YFP transduced CB cells. Cells derived from the NOD/SCID BM 8 weeks post transplantation 
was stained with CD34 and CD38 markers simultaneously and separately for cKIT. The mean 
percentage (± SEM) of YFPP+ CD34+, CD34+ and CD38+, CD34+ and CD38- cells, and cKIT+ cells are 
represented here. * P < 0.05 indicates statistically significant differences from the controls.  
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4.13 Constitutive expression of ABCG2 does not change the 
SRC frequency 
To determine if ABCG2 affects the frequency of SRC, limiting dilution analysis in 
NOD/SCID mice were performed. CB derived CD133+ cells were transduced with 
ABCG2-YFP and YFP vectors and transplanted into sublethally irradiated NOD/SCID 
mice in limited numbers without any pre-sorting. The ABCG2-YFP transduction 
generates one third the amount of YFP+ CD34+ cells, therefore 3 fold more total cells 
were injected into mice transplanted for ABCG2-arm. The exact numbers of 
transplanted CD34+YFPP+ cells were determined 48 hours after the final transduction 
and used later for calculation of the frequencies of SRC. The mice were sacrificed 
after a period of 6 weeks and the BM analysed for the presence of multilineage cells. 
 
Table 4.4 Limiting dilution assay of CB cells transduced with ABCG2-YFP and YFP vectors. 
Phenotype No. of YFP+ CD34+ 
cells transplanted 
No. of positive 
mice/total no. 
SRC frequency (upper & 
lower limits) 
133000 3/3 
32000 0/4 
YFP 
8000 1/6 
1/80 000 
(1/47 705 -1/132 724) 
 
114000 3/3 
28500 2/5 
ABCG2-YFP 
7130 0/2 
1/47 000 
(1/28 572 -1/75 783) 
 
 
As shown in table 4.4, all of the mice (3/3) transplanted with highest dilution of cells 
(1.14- and 1.33 x 105 of ABCG2 and YFP-transduced CD34+cells respectively), were 
found to be multilineage engrafted. In the middle dilution (injected 2.85- and 3.2 x 
104 CD34+ YFP+ of ABCG2 and YFP-transduced CD34+cells respectively per 
mouse) showed no engrafted mice in the cohort of YFP mice. In contrast, 2 mice 
(2/5) transplanted with ABCG2 transduced cells were found to be multilineage 
engrafted. In the lowest dilution of cells injected (1.12 x104 of ABCG2-YFP and YFP 
transduced CD34+ cells), none of the mice transplanted with ABCG2 cells were 
found to be engrafted. However one mouse (1/6) transplanted with YFP transduced 
cells showed multilineage engraftment. Based on these limiting dilution results, the 
Results 
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frequencies of SRC in the transduced CB cells (calculated using L-calc. software), 
were estimated to be 1/47 000 ABCG2-YFP transduced CD34+ cells and 1/80 000 
YFP transduced CD34+ cells. Taken together, these results suggest that ABCG2 
does not drastically increase the SRC frequency in the NOD/SCID mice.
Discussion 
 
5 Discussion 
 
A unique property of HSC is the ability to efflux fluorescent dyes such as Hoechst 
33342 and Rhodamine 123 and this property has been attributed to the ABC drug 
transporters ABCG2 and MDR1, respectively. ABCG2, a member of the G-subfamily 
of ABC transporters, is highly expressed in haematopoietic stem cells but is turned 
off in most committed progenitors and differentiated cells, suggesting a role in early 
haematopoietic cells (Scharenberg et al., 2002). A distinct population of BM cells 
expelling the Hoechst dye can be defined by flow cytometry and this population 
(termed side population) is enriched in HSC in mice (Goodell et al., 1996) as well as 
in humans (Feuring-Buske and Hogge, 2001; Uchida et al., 2001). Targeted gene 
ablation studies in mice have revealed that SP cell phenotype in haematopoietic 
cells is determined by Abcg2. Another ABC drug transporter that is overexpressed in 
HSC is MDR1. Several lines of evidence suggest that MDR1 expression is 
conserved in HSC. Previous studies have demonstrated that retroviral vectors 
expressing MDR1 in murine haematopoietic progenitors resulted in an expansion of 
murine BM cells. A myeloproliferative disorder developed in mice transplanted with 
such expanded cells (Bunting et al., 1998). On the other hand, the expression of 
human ABCG2 in mouse BM cells significantly blocked haematopoietic development 
leading to speculation that ABCG2 expression might play a role in early stem cell 
self-renewal by blocking differentiation. Studies in a non-human primate model 
demonstrated that forced expression of ABCG2 in bone marrow stem cells of rhesus 
macaques does not interfere with haematopoietic stem cell maturation in vivo (Ueda 
et al., 2005). However, till date there has been no study analyzing the role of ABCG2 
in primitive human hematopoiesis. 
The establishment of a retroviral transduction model to constitutively express ABCG2 
in human CD133+ cells has allowed us to investigate its role in primary human 
haematopoietic stem and progenitor cells. In this gene transfer model, CB derived 
CD133+ cells were activated into cell cycle by a combination of stimulatory cytokines, 
and subsequently transduced with retroviral supernatant from producer cells. CD133, 
the novel marker present on primitive haematopoietic cells, was used for isolation of 
HSC using MACS technique. Isolation procedures yielded highly pure CD133+ cells. 
CD133 is a good substitute of the more commonly used marker CD34 as it is 
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expressed on most of the CD34+ cells, and additionally, it comprises a small subset 
of very early haematopoietic CD133+ CD34- stem cells that are believed to be even 
more primitive than the CD34+ cells (Gallacher et al., 2000). Transduced CD133+ 
cells were purified by FACS and plated in different in vitro assays representing 
different stages of primitive haematopoietic stem and progenitor cell development. 
Our in vitro results indicate that the constitutive expression of ABCG2 enhances the 
formation of clonogenic progenitors with an increase of all clonogenic progenitor 
cells. This effect was mostly pronounced in the most immature clonogenic progenitor 
cells, the CFU-GEMM. In addition to the increase of the number of clonogenic 
progenitors we also observed a higher proliferative capacity as compared to the 
empty vector control with a higher number of secondary colonies formed by those 
cells constitutively expressing ABCG2. It is important to note that the constitutive 
expression of ABCG2 did not have any positive effect on the cell expansion in liquid 
culture as well as the LTC-ICs. However the differentiation of LTC-IC into clonogenic 
progenitors after 6 weeks in culture was again found to be enhanced by the 
expression of ABCG2. This indicates that ABCG2 was able to positively influence the 
colony formation ability of the LTC-IC. These observations suggest that ABCG2 
plays a strong role in the differentiation and proliferation of clonogenic progenitors 
developing from primitive haematopoietic stem cells. In order to characterize the role 
of ABCG2 in the most primitive haematopoietic stem cells represented as long-term 
reconstituting stem cells in immunodeficient mice we transplanted sublethally 
irradiated NOD/SCID mice as previously described (Buske et al., 2002; Dick et al., 
1997; Glimm et al., 2001).  Cells capable of multilineage repopulation of transplanted 
NOD/SCID mice, termed as SCID repopulating cells (SRC) represent the most 
primitive haematopoietic stem cells identifiable in vivo. In our experiments, sub-
lethally irradiated NOD/SCID mice were injected with ABCG2 and control vector 
transduced cells. Transduced cells could be easily followed due to YFP labelling and 
multilineage engraftment was studied 8 weeks post transplantation. ABCG2 
expression induced a clear reduction in the development of B-lymphoid cells and an 
increase in the number and proportion of myeloid cells engrafted in NOD/SCID mice, 
leading to an inversion of the lympho-myeloid ratio. A similar inversion of the lympho-
myeloid ratio has been observed in SRC transduced with HOXA10 (Buske et al., 
2001), due to an impairment of B-cell development. However, this is the first study to 
demonstrate that the constitutive expression of an ABC transporter in primitive 
progenitors can lead to such a drastic effect on the lympho-myeloid ratio of cells 
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generated in NOD/SCID mice. This observation suggests that ABCG2 either alters 
the cell fate decisions of multipotent cells with myeloid and lymphoid differentiation 
capacity, or influences a subset of committed myeloid or lymphoid progeny to 
produce altered frequencies of mature cells. The observation that differentiated 
myeloid progeny are generated from ABCG2 transduced SRC leads us to conclude 
that myeloid differentiation is not perturbed and that the increase in myeloid cells 
observed is not due to an accumulation of undifferentiated myeloid cells. Since the 
NOD/SCID assay for human repopulating cells does not readily detect differentiation 
into the T-cell lineage, use of alternative recipients capable of supporting human T 
lymphopoiesis will be required to determine whether ABCG2 expression affects 
lymphoid T-cell development.  
In this study we also analyzed the impact of ABCG2 expression on the primitive 
human haematopoietic cells in the NOD/SCID mice. Our results indicate that the 
constitutive expression of ABCG2 does not affect the number of most primitive 
human CD34+ CD38- cells in the NOD/SCID mice, but increases the number of the 
more differentiated CD34+ CD38+ cells known to comprise the fraction of clonogenic 
progenitors. This result is consistent with our in vitro results that demonstrate an 
enhancement of clonogenic progenitors. In order to find out the frequencies of SRC 
in CD34+ cells transduced with ABCG2, we performed the CRU assay. Transduction 
of cells with ABCG2 showed only a meagre increase of the CRU frequency in the 
NOD/SCID mouse model as compared to the empty vector control. This result leads 
us to conclude that ABCG2 overexpression does not affect the primitive 
haematopoietic stem cell with SCID repopulating properties in a positive manner and 
perhaps only regulates the generation of clonogenic progeny from primitive 
haematopoietic cells.  
Our data characterize ABCG2 as a previously unknown positive regulator of human 
hematopoiesis. There is no previous indication from the literature that an ABC 
transporter can regulate hematopoiesis.  Our hypothesis that ABCG2 plays an 
important role in haematopoietic stem cell regulation is supported by reports that 
ABCG2 expression is restricted to early haematopoietic cells with a decrease of 
expression levels during cell differentiation (Zhou et al., 2001). The mechanism by 
which ABCG2 achieves this effect on haematopoietic progenitors remains to be 
elucidated and these efforts will be facilitated by preliminary microarray data that 
identify regulated genes in response to ABCG2 overexpression as well as by 
identification of substrates that might mediate such effects on HSC. 
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6 Summary 
 
ABCG2 is a transporter protein that has the ability to efflux many drugs and 
fluorescent dyes. Primitive haematopoietic stem cells highly express ABCG2 and the 
expression level decreases as these cells differentiate indicating a possible role of 
this transporter in HSC. In the present study, we have analyzed the role of ABCG2 in 
early haematopoietic stem cells by constitutively expressing ABCG2 in human CB 
derived CD133+ cells. This constitutive expression of ABCG2 demonstrated an 
enhancement of primary CFCs in vitro, including the most primitive clonogenic cells 
the CFU-GEMM (n=12, p<0.002). ABCG2 enhances the replating capacity of primary 
colonies with a mean 3.0 fold increase in the number of 2nd colonies (n=9, p<0.01), 
indicating a substantial enhancement of the proliferative potential of clonogenic 
progenitors by constitutive ABCG2 expression. Overexpression of ABCG2 did not 
have any positive effect on cell expansion in liquid culture as well as the frequency of 
LTC-IC, however, the production of CFC per LTC-IC was found to be enhanced, 
again supporting the fact that ABCG2 might play an important role in the 
differentiation and proliferation of clonogenic progenitors.  
Using the NOD/SCID mouse model, we were able to demonstrate that enforced 
expression of ABCG2 in human primitive haematopoietic cells leads to inversion of 
lymphoid-myeloid ratio, suggesting that ABCG2 perhaps alters the cell fate decisions 
of multipotent cells with myeloid and lymphoid differentiation capacity. An enhanced 
production of differentiated myeloid cells was observed on ABCG2 overexpression. 
In order to analyze the effect of ABCG2 on early haematopoietic cells, NOD/SCID 
mice transplanted with CB cells either expressing ABCG2 or the empty viral vector, 
were analyzed for the presence of HSC. Although the number of human CD34+ 
CD38- cells did not show any difference, the number of CD34+ CD38+ progenitor 
cells was significantly increased (n=5, p<0.05), indicating that ABCG2 plays a role in 
the differentiation of clonogenic progenitors. CRU assays were performed to detect 
the effect of ABCG2 expression on the frequency of SRC and did not show any 
significant increase in the frequency of SRC. 
Taken together, these results indicate that ABCG2 is a potent positive regulator of 
human hematopoiesis at the level of early haematopoietic development.
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7 Zusammenfassung 
 
ABCG2 gehört zur Gruppe der ATP-bindenden Transportproteine, die die Fähigkeit besitzen, 
viele Wirkstoffe, wie z.B. Zytostatika und fluoreszierende Farbstoffe aus der Zelle zu 
befördern. ABCG2 weist ein stammzelltypisches Expressionsprofil auf, mit einer hohen 
Expression in den frühesten hämatopoetischen Stammzellen (HSZ) und einer Abnahme bis 
zum Verlust der Expression in reifen Blutzellen. Dieses Stammzelltypische Expressionsprofil 
weist auf eine mögliche Rolle von ABCG2 in der Stammzellentwicklung und –differenzierung 
hin. In der vorliegenden Studie war es unser Anliegen, durch die konstitutive Expression von 
ABCG2 in humanen, aus Nabelschnurblut stammenden CD133 - positiven Zellen, die Rolle 
von ABCG2 in frühen hämatopoetischen Stammzellen zu untersuchen. Die konstitutive 
Expression von ABCG2 führte in vitro zu einem Anstieg klonogener Progenitorzellen, 
einschließlich der primitivsten klonogenen Progenitorzellen, der CFU-GEMM (n=12, 
p<0,002). Die konstitutive Expression von ABCG2 führte weiterhin zu einem Anstieg des 
proliferativen Potentials klonogener Progenitorzellen um den Faktor 3,0, ablesbar an der 
Anzahl sekundärer Kolonien (n=9, p<0,01). Um die Rolle von ABCG2 auf der Ebene der 
hämatopoetischen Stammzelle zu untersuchen, führten wir stromazell-abhängige und 
serumfreie Langzeitkulturen durch, und transplantierten NOD/SCID Mäuse mit 
Nabelschnurblutzellen, die konstitutiv ABCG2 exprimierten. Wir konnten zeigen, dass die 
konstitutive Expression von ABCG2 die Frequenz HSZ sowohl in vitro als auch in vivo nicht 
ändert, die Produktion klonogener Progenitorzellen pro LTC-IC aber steigert. Auch im 
NOD/SCID Mausmodell konnten wir zeigen, dass die CRU-Frequenz zwar nicht gesteigert 
wurde, und auch die Anzahl an humanen CD34+ CD38- Zellen in Mäusen, die mit 
Nabelschnurblutzellen transplantiert wurden, die retrovirales ABCG2  exprimierten, nicht 
verändert, die Anzahl reiferer CD34+ CD38+ Progenitorzellen aber signifikant erhöht war 
(n=5, p<0,05). Um zu überprüfen, ob das Differenzierungsmuster repopulierender 
Stammzellen durch ABCG2 verändert wird, haben wir das immunphänotypische Profil mittel 
Durchflusszytometrie überprüft und konnten zeigen, dass die konstitutive Expression von 
ABCG2 zu einer Umkehr des lympho-myeloischen Engraftments mit einem Überwiegen der 
myeloischen Repopulation führte. Die Tatsache, dass trotzdem ein multilineäres 
Engraftment zu beobachten war, weist daraufhin, dass ABCG2 einen Einfluss auf der Ebene 
der multipotenten hämatopoetischen Progenitorzellen hat.  Sowohl in vitro als auch in vivo 
induzierte ABCG2 keine maligne Transformation hämatopoetischer Zellen.  
Zusammengefasst lässt sich somit sagen, dass ABCG2 ein wirksamer positiver Regulator 
der humanen Hämatopoese, vor allem im frühen Stadium ist.       
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